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CHAPTER I 
INTRODUCTION 
The major portion of carbon oxidized in biological systems passes through pyruvate 
dehydrogenase on its way to the citric acid cycle. Pyruvate dehydrogenase requires 
thiamine pyrophosphate (TPP), flavin adenine dinucleotide (FAD), coenzyme A, 
nicotinamide adenine dinucleotide (NAD+) and lipoic acid cofactors. While all of the 
cofactors are required for pyruvate dehydrogenase function, only lipoic acid requires 
enzymatic assistance for incorporation and removal from the complex. 
A. Lipoic Acid Discovery 
Lipoic acid (l ,2-dithiolane-3-pentanoic acid or DL-6,8-thioctic acid, also known as 
protogen A, acetate replacing factor and pyruvate oxidation factor) was first isolated from 
liver in a cooperative effort by L.J. Reed, LC. Gunsalus and the Eli Lilly Company in the 
early 1950's (1). The 8 carbon compound contains a carboxyl group and a thiolane ring 
that is convertible to a dithiol form with reducing agents. The structures of the 
interconvertible forms, lipoic acid and dihydrolipoic acid, are shown in Fig. I-1. 
1 
0 
II 
C 
""" :,.,, HO/ 
s-s HS SH 
Figure 1-1. Lipoic Acid. Shown in its oxidized (left) and reduced (right) form. 
By 1957 L.J. Reed et al. (2) had presented evidence that protein-bound lipoic acid is 
involved in the oxidative decarboxylation of a-keto acids by a-keto acid dehydrogenases. 
Lipoic acid is essential to the function of all a-keto acid dehydrogenases and the glycine 
cleavage system. In 1960 Nawa et al. (3) showed that protein bound lipoic acid is attached 
by its carboxyl group through an amide linkage to the £-amino group of a lysine residue as 
shown in Fig. I-2. 
s-s 
E2 
Figure 1-2. Protein Bound Lipoic Acid in an Amide Linkage to the E-NH2 of 
Lysine. E2 designates the amino acid backbone of the E2 subunit of a-keto acid 
dehydrogenases. The structure gives a flexible arm 14 angstroms long. 
B. Lipoic Acid Biosynthesis 
In Eschericia coli lipoic acid is synthesized from octanoyl-ACP (acyl carrier protein) 
by the addition of sulfur to the number 6 and 8 carbons [Morris et al. (4)]. Hayden et al. 
(5, 6) showed that the E. coli gene lipA is involved in the sulfur insertion and is similar to 
the system for biotin synthesis. The lipB gene, identified by K.E. Reed et al. (7) is 
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involved with lipoic acid synthesis after sulfur insertion. Further work by Morris et al. (8) 
showed lipB and another gene, lplA, coded for ligases responsible for the attachment of 
lipoic acid to proteins. These enzymes have substrate specificity differences: lipB prefers 
lipoic acid but will incorporate octanoic acid in the absence of lipoic acid while lplA will 
only use lipoic acid. Siggaard-Anders et al. (9) reported that, in E. coli, a ~-ketoacyl-
[ACP] synthase condenses octanoic acid with ACP to supply octanoic acid for lipoic acid 
biosynthesis. The authors speculated that a similar enzyme would function in plant 
mitochondria. 
In eucaryotes fatty acid synthesis generally occurs in the cytosol. However, Wada 
et al. (10) identified a complete fatty acid synthesis system in pea mitochondria as had been 
speculated by Siggaard-Anders et al. (9). This system uses ACP to make fatty acids of 
shorter chain length than made by the system found in plastids, and the investigators 
suggested that most of the fatty acids synthesized by this system are used for lipoic acid 
biosynthesis. Sulo et al. (11) identified the yeast gene LIPS by its ability to complement a 
mutant with a defective lipoic acid synthesis system. The LIPS sequence contains a 
mitochondria targeting sequence in the leader peptide and is homologous to the lipA of E. 
coli, which is responsible for the sulfur insertion step. Recently Brody et al. (12) reported 
that the Saccaromyces cerevisiae mitochondrial ACP is also involved in synthesis of short 
chain fatty acids and that an ACP 1 mutant had only 5-10% the normal level of lipoic acid. 
Jordan and Cronan (13) found that E. coli and mitochondria of higher plants can transfer 
lipoic acid directly from ACP to lipoic acid-dependent enzymes. All of these data indicate 
that biosynthesis of lipoic acid is a special case of fatty acid biosynthesis. Instead of being 
synthesized in the cytosol like most fatty acids, lipoic acid is made in the same subcellular 
compartment as many of the proteins for which it is a vital component. 
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C. Other Lipoic Acid Functions 
Lipoic acid is currently receiving attention as a general anti-oxidant and specifically 
for helping prevent or reduce damage due to reactive oxygen radicals in diabetes, radiation 
exposure, and cardiac and cerebral ischemia (14). In addition putative lipoyl domains have 
been found in proteins in which they have as yet no known function ( 15) . 
D. a-Keto Acid Dehydrogenases 
The a-keto acid dehydrogenase family of multi-enzyme complexes catalyzes the 
oxidative decarboxylation of substrate to form an acyl-coenzyme A and NADH. This 
family has three members, pyruvate dehydrogenase, a-ketoglutarate dehydrogenase and the 
branched chain a-keto acid dehydrogenase. Pyruvate dehydrogenase (PDH) converts 
pyruvate to acetyl-coenzyme A (acetyl-CoA) for the citric acid cycle, fatty acid biosynthesis 
and for acetylcholine synthesis. a-Ketoglutarate dehydrogenase converts a-ketoglutarate to 
succinyl-CoA in the citric acid cycle. The branched chain a-keto acid dehydrogenase 
utilizes multiple substrates in the degradation of branched chain amino acids. 
These multienzyme complexes have at least three components with catalytic activity; 
an a-keto acid dehydrogenase (El), a dihydrolipoyl transacylase (E2) and a dihydrolipoyl 
dehydrogenase (E3). The overall reaction catalyzed by these complexes is: 
0 TPP,Upo~e,FAD O 
II # 0 
R~c.( + CoASH 
0-
+ NAO+ ---~---'--->- R~--SCoA + NADH + CO2 + H+ 
The El subunit decarboxylates the a-keto acid in a thiamine pyrophosphate-dependent 
(TPP) reaction with the formation of a hydroxyalkyl-TPP intermediate. The hydroxyalkyl-
TPP is then oxidized by lipoamide to form an acyl-TPP. The acyl group is transferred to 
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an E2-lipoamide. The acyl group is then shuttled via multiple lipoamides to the transacylase 
active site on the E2 subunit where it is finally transferred to CoA through a acyl transfer 
reaction with the formation of dihydrolipoamide and the release of acyl-CoA. A FAD 
associated with the E3 subunit then regenerates the lipoamide and is in tum reoxidized by 
NAD+ (Fig. I-3). The lipoamide of E2 is lipoic acid attached to the c:-amino group of lysine 
forming a 14 Angstrom long flexible swinging arm. 
OH 
I 
[RC--TPP] 
El 
[TPP] 
2 
r~ 
[R] 
-SH HS-
[FAD] 
HS) 
E2 HS~ 
E3 
[FAD] 
-S-S-
?i j!_R] 0 
RC-S) 3 ii 
HS~ RC-SCoA 
[R] CoASH 
NAD+ 
NADH 
+H+ 
Figure I-3. Reactions of the a-Keto Acid Dehydrogenases. Five reactions are 
carried out by three enzyme subunits resulting in one acyl-CoA and one NADH generated 
per a-keto acid molecule reacted. 
E. Regulation 
Procaryotic complexes are controlled by product inhibition by both NADH and 
acyl-CoA. There is no kinase or phosphatase component in procaryotic a-keto acid 
dehydrogenase regulation. 
The eucaryotic dehydrogenase complexes have, in addition to El, E2, and E3, an X 
subunit which has a lipoyl domain. Recently X was designated E3BP (E3 binding protein) 
(16) as it is involved in the contact between the E2 core and E3 dimers. The lipoyl moieties 
of X may have a role in the catalytic activity of the complex and X is involved with 
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regulation of the complexes through interactions with a kinase (16). Since eucaryotic a-
keto acid dehydrogenases are regulated by phosphorylation/dephosphorylation there are 
kinase and phophatase requirements (16). 
F. Structure 
The a-keto acid dehydrogenases are very large self-assembling complexes 
composed of multiple copies of the three subunits. The E2 subunits form the core of the 
complex. In E.coli there are 24 E2 subunits around which 12 E3 homodimers and 12 El 
monomers associate forming a -4600 kDa complex (Fig. I-4) ( 17). 
Using trypsin and lipoamidase on E. coli a-keto dehydrogenases Stepp et al. ( 18) 
discovered the domain nature of the E2 subunit. Treatment of the complex with trypsin 
revealed a sensitive flexible region in the E2. Cleavage at this flexible region released 
polypeptides with lipoic acid attached whereas treatment with lipoamidase released only 
lipoic acid. Interestingly about half of the lipoyl domains in the complex could be released 
with no significant loss of overall dehydrogenase activity. Later work using trypsin and 
Staphylococcus aureus VS proteinase and then sequencing of the released peptides showed 
that cleavage occurred in stretches of the protein which are rich in alanine, proline and 
charged amino acids ( 19). These stretches have conformational flexibility and are probably 
involved in lipoyl domain movement. The E. coli PDH can assemble and carry out full 
catalytic activity after deletion of two of its three lipoyl domains (20) from the E2 subunits. 
These results indicate a complex mechanism for the shuttling of acyl groups among active 
sites. By using a computer modeling system with E.coli complex data Hackert et al. (21) 
calculated that two lipoyls are available at each El active site and suggested a lipoyl-lipoyl 
transfer network that shuttles electrons and acyl groups around the complex. Figure I-5 
shows a schematic representation of the lipoyl-lipoyl transfer network. 
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- E2 (dihydrolipoyl 
t ransacetylase) 
monomer 
E1 (pyruvate 
dehydrogenase) 
dimer 
•• E3 (dihydrolipoyl 
dehydrogenase) 
dimer 
E2 24-mer 
particle 
Pyruvate 
dehydrogenase 
60-subun it 
complex 
Figure 1-4. PDH Subunit Arrangement. (Diagram was downloaded from 
www.biochemtech.uni-halle.de/PPS2/course/section 11/pdhcomp.gif. It was adapted from 
Voet and Voet (1 990) after Lester Reed). 
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Figure I-5. Lipoyl Group Shuttle Network ( 16). Dashed line circles represent E2 
subunits with lipoyl domains indicated by lipoic acid, the lysine attachment is not shown. 
Dark lines represent potential pathways for electron and acyl group transfer. 
The organization of E2 subunits is similar across species in that the amino terminal 
region contains the lipoyl domains followed by the E3 binding domain and the 
dihydrolipoyl transacylase catalytic domain with the El binding domain at the carboxyl 
terminus. The number of lipoyl domains in each E2 varies with organism: E. coli a-keto 
glutarate DH has one, E. coli PDH has three, mammalian PDH has two and mammalian 
branched chain DH has one (22) (Fig. I-6). 
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Inner core 
Lipoyl domain E3 binding Acyl transferase 
E1 binding 
Escherichia cc/i 
Bovine liver 
Yeast E2 
L = lipoyl 
80 144 180 218 380 
Yeast X 
Figure 1-6. Domain Structure and Lipoylation Pattern of Various E2 
Subunits. All structures shown are of the indicated species PDH. Yeast X indicates the 
X or E3 binding protein. 
Sequence analysis of 12 E2 subunit lipoyl domains reveals considerable conservation in the 
eleven amino acids around the lipoic acid attachment site as follows: 
L4 E9 S5 D9 *K 12 A10 S8 M6 E7 V6 P8 
(Subscripts indicate the number of sequences in which the given amino acid is present and 
*Kindicates the point of lipoic acid attachment.) 
G. Activating System 
Lipoic acid is covalently attached to the side chain of lysine residues in the enzymes 
in which it occurs. The lipoic acid is added to a-keto acid dehydrogenases as a post 
translational modification. In Enterococcus faecalis this is done by an enzyme system that 
requires ATP and Mg2+ and can be separated into two fractions, both are required for 
attachment (2). The reaction scheme in which AEI activates lipoic acid by coupling it to 
AMP and then AE2 transfers the lipoyl moiety to the £-amino group of lysine is shown in 
Fig. I-7. 
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AEl + ATP + Lipoic Acid ¢::> AEl-lipoyl-AMP + PP 
AEl-lipoyl-AMP + AE2 ¢::> Lipoyl-AE2 + AMP + AEl 
Lipoyl-AE2 + apo-PDHC ::::} Lipoyl-PDHC + AE2 
Figure 1-7. Reactions of the Lipoic Acid Activating System of E. faecalis. 
AEI indicates activating enzyme 1 of the activating system and AE2 indicates activating 
enzyme 2 of the activating system, PP is pyrophosphate, apoPDHC is inactive pyruvate 
dehydrogenase complex without lipoic acid. 
In E. coli all of the catalytic functions required for lipoic acid attachment are carried 
out by a single enzyme; however there are two pathways for lipoic acid ligation involving 
different enzymes. The enzyme produced by the lplA gene is responsible for the 
attachment of exogeneously supplied lipoic acid and the lipB gene product utilizes 
endogeneously synthesized lipoic acid (4, 8). E. coli lipoyl ligases are cross-species-active 
as the human inner lipoyl domain cloned into E. coli is properly lipoylated (23). Jordan 
and Cronan ( 13) showed that lipoic acid can also be attached by transfer directly from the 
acyl-carrier protein of the lipoic acid biosynthetic machinery to lipoic acid dependent 
enzymes without an ATP requirement in E. coli and mitochondria. These results provide 
the link between lipoic acid biosynthesis and lipoic acid ligation in E. coli and eucaryotic 
mitochondria. 
Attachment of lipoic acid is similar in mammals to that of E. faecalis requiring two 
enzymes. Lipoate activating enzyme (24) generates lipoyl-AMP and then lipoyltransferase 
attaches lipoic acid to the lipoate-dependent enzymes. Fujiwara et al. (25) recently isolated 
two isoforms of bovine lipoyltransferase, LipTI and LipTII, and cloned and sequenced the 
LipTII cDNA. It contained a 1119 base pair reading frame encoding 373 amino acids with 
a 26 amino acid mitochondrial targeting sequence. The predicted amino acid sequence 
showed 35% identity to E. coli lipoate-protein ligase A (the lip/A gene product). 
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H. Lipoamidase 
1. Early Observations and S. faecalis 
Seaman (26-28) treated crude tissues or cell extracts with adsorption alumina and 
observed a lowering of the lipoic acid content of the a-keto acid dehydrogenases. This 
effect required the presence of an enzyme which released protein bound lipoic acid. In 
1958 Reed et al. (29) reported that an enzyme in Streptococcus faecalis inactivated E. coli 
PDH by removing bound lipoic acid (Fig. 1-8) and that subsequent incubation with lipoic 
acid, ATP and a lipoic acid activating enzyme system restored PDH activity. This lipoic 
acid liberating enzyme was named lipoyl-X-hydrolase. An enzyme with similar hydrolase 
properties was reported from bakers' yeast (30). In 1963 Suzuki and Reed (31) reported 
on additional substrate specificity and devised a procedure for a 100-fold purification of 
lipoamidase from S.faecalis. The enzyme hydrolyzed methyl lipoate, lipoamide and £-N-
lipoyl-L-lysine and other lipoyl amino acids but not £-N-biotinyl-L-lysine, £-N-acetyl-L-
lysine or £-N-benzoyl-L-lysine. Based on the substrate specificities they called the enzyme 
lipoamidase instead of lipoyl-X-hydrolase. The enzyme has not been found in E. coli 
(Crookes Strain) (32, 33). 
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Figure. 1-8. Lipoamidase Reaction. The structure on the left is lipoic acid attached 
to the E-NH2 of a lysine in the dihydrolipoyl transacetylase (E2) subunit. 
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2. Mammalian Lipoamidase and Relation to Biotinidase 
No further work on lipoamidase was reported until 1987 when Oizumi and 
Hayakawa investigated mammalian lipoamidase. They devised an HPLC assay for 
lipoamidase based on the synthetic substrate lipoyl-pABA (LA-pABA) (34) and then 
examined various tissues from various organisms for lipoamidase. The assay detected a 
lipoamidase in human serum which has a pH optimum of 7 (35). A breast milk 
lipoamidase was purified 4,400-fold. The protein is a 135 kDa glycoprotein with a pl of 
4.2, a pH optimum of 7, and has serine hydrolase properties (36). In various guinea pig 
tissues most lipoamidase activity occurs in a liver membrane fraction and the presumed 
protein has serine amidase properties. The active protein has a pl of 5.7 and an apparent 
molecular weight of 60 kDa by SDS-PAGE and 120 kDa by native PAGE (37). Human 
serum lipoamidase liberated lipoic acid from bovine PDH only after treatment with trypsin 
(38). It was speculated that the enzyme probably only functions in lipoic acid salvage. An 
enzyme from pig brain membrane fractions was purified by affinity chromatography using 
an Arg-Phe-NH2 column (lipoyl based affinity columns were not effective) (39). The 
interaction of chelated iron with the pig brain lipoamidase was studied and it was found that 
chelated iron inhibits the enzyme while free iron does not (40). 
Backrnan-Gullers et al. (41) compared human serum and breast milk lipoamidase 
using LA-pABA and Iipoyl-lysine as substrates. In serum LA-pABA and lipoyl-lysine 
cleaving activities responded differently to inhibitors suggesting different enzymes were 
responsible for the activity. They dubbed these lipoyl-lysine hydrolase (LLH) and lipoyl-
pABA hydrolase (LPH). LLH was activated by thiol compounds and EDTA and was 
inhibited by sulfhydryl-inhibitors while LPH was not activated by thiols or EDTA but was 
inhibited by sulfhydryl-inhibitors. In breast milk LA-pABA and lipoyl-lysine cleaving 
activities were unaffected by any of the reagents that affect the serum activity. Serum LLH 
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and possibly LPH are cysteine hydrolases while no inference was made about milk 
lipoamidase. Using various tissues from rat and comparing lipoamidase and biotinidase 
activity Nilsson et al. concluded that liver LLH is definitely different from LPH and in fact 
LLH is biotinidase ( 42). 
Other labs also noted inconsistencies in what was reported as lipoamidase. 
Specifically, Garganta et al. ( 43) concluded that pH profiles, molecular weight, 
thermostability profiles and inhibition by p-HMB and PMSF provided ample evidence that 
human serum lipoamidase is really biotinidase. Further evidence included the finding that a 
monospecific polyclonal antibody raised against biotinidase precipitated 95% of both 
lipoamidase and biotinidase activity and that children with profound biotinidase deficiency 
also had drastically reduced lipoamidase activity (43). Thus, most if not all, lipoamidase 
activity in serum is due to biotinidase. 
Nilsson et al. ( 44) showed a concomitant deficiency in serum lipoamidase activity 
in a 21 month old boy with profound biotinidase deficiency using both the LA-pABA and 
biotinyl-lysine assays. They concluded that lipoarnidase and biotinidase are the same 
enzyme. However a small amount of residual activity was seen using the LA-pABA assay. 
The investigators suggested that a small amount of modified biotinidase probably exists. In 
another study Nilsson et al. ( 45) showed that human serum lipoamidase and biotinidase 
activities copurified through 7 different purification steps. The resulting enzyme had a 
molecular weight by SDS-PAGE of 76 kDa and a pl of 4. 
Hui et al. (46) cleaved the human milk lipoamidase with endoproteinase Lys-C and 
performed gas phase microsequencing on the resulting peptides. Sequence analysis 
showed this enzyme to be the bile salt-stimulated lipase (pancreatic cholesterol esterase EC 
# 3. 1.1.13). They then cloned and expressed a recombinant rat pancreatic cholesterol 
esterase which showed both lipolytic and lipoamidase (LA-pABA cleavage) activity. 
Mutagenesis of the recombinant gene by an amino acid substitution known to abolish 
esterase activity (His435~Gln435) resulted in loss of the lipolytic but not the lipoamidase 
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activity. The authors state that an enzyme in the digestive tract which is capable of both 
lipoylitic and lipoarnidase activity must be of great importance in digestion and absorption 
of nutrients. 
Further work on the pig brain enzyme by Oizurni et al. (47, 48) showed that >95% 
of the lipoarnidase activity comes from membrane fractions. The enzyme was purified 
-600 fold; it is a 140 kDa glycoprotein that hydrolyzes lipoyl-lysine but not biotinyl-lysine. 
It requires lipoic acid in the substrate but it hydrolyzes amide, ester or peptide bonds and 
thus has loose specificity as to the attachment site of lipoic acid. They classified this 
enzyme as a multiple hydrolase with an unknown function. Since the enzyme was 
membrane associated, they examined the effect of phospholipids and found that 
phosphatidylethanolarnine induced a 2-fold increase in activity but that phosphatidylserine, 
cardiolipin, and phosphatidic acid induced an 80% reduction in activity ( 49). Subsequent 
studies showed that the pig brain enzyme releases membrane bound proteins which are 
glycosyl-phosphatidylinositol bonded and those which are myristolated but not integral 
membrane proteins. This activity was inhibited by lipoyl-lysine (50). 
In summary, prokaryotic lipoamidase has been studied only briefly. It has been 
partially purified and found to cleave substrates with lipoic acid in an amide bond to a 
variety of other molecules including protein bound lysine but little else is known. 
Eucaryotic lipoamidases from many sources have been studied extensively and the proteins 
range in size from 60. kDa to 140 kDa. The substrate specificity ranges from simple LA-
pABA to the phosphatidylinositol tail of membrane associated proteins. Some enzymes 
with lipoarnidase activity also have biotinidase or pancreatic cholesterol esterase activities. 
I. Purpose of This Work 
All of the enzymes concerned with the a-keto acid dehydrogenases, the attachment 
of lipoic acid to the £-NH2 of lysines, and the regulation of PDH complex activity have 
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been cloned and sequenced. Lipoamidase is the only enzyme that has not been cloned and 
sequenced. 
Given the ambiguities about mammalian lipoamidases and the fact that E. faecalis 
lipoamidase has been partially purified, I chose the enzyme from E. faecalis as the starting 
point for further study of lipoamidase. The goal was to purifiy lipoamidase (from E. 
faecalis) either to homogeneity or to obtain sufficient purity so that a partial amino acid 
sequence could be determined. The partial amino acid sequence would make possible the 
construction of a nucleic acid probe to screen the existing E. faecalis 1 OC 1 library. 
The utility of lipoamidase in investigating the role of lipoyl moieties in various 
functions within the a-keto acid dehydrogenase complex has been established by Dr. 
Thomas Roche's group. Specifically, Stepp et al. (18) used lipoamidase and trypsin 
treatment in developing the lipoyl domain concept in E2 structure. 
Potential uses of purified lipoamidase include study of: 
1) role of lipoyl moieties in phosphorylation and dephosphorylation. 
2) role of lipoyl moieties in proteins whose function is unknown. 
3) role of lipoyl moieties in protein X function. 
4) role of lipoyl moieties in the autoimmune disease, primary biliary cirrhosis. 
The physiological function of lipoamidase has not been established. Is it a lipoic 
acid salvage enzyme? Does it have a role in the regulation of lipoyl-dependent enzymes? 
Or is it part of a multifunctional enzyme which includes one or both of these functions? 
There are many important questions that could be answered by an intensive study of 
lipoamidase. 
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CHAPTER II 
MATERIALS AND METHODS 
A. Materials 
All chemicals and materials were from Sigma unless specifically indicated 
otherwise. Skim milk and tomato juice were from a local grocery store. Yeast extract and 
tryptone were from Difeo. Casein was from United States Biochemical. Salts in the 'Salts 
B' solution were from J.T. Baker. 
B. Growth of Lipoic Acid Deficient Enterococcus faecalis 
Enterococcus faecalis (E. faecalis) was obtained from American Type Culture 
Collection, (ATCC #11700, strain lOCl). The dehydrated culture was rehydrated in 0.4 
ml of ATCC medium #17 (Table 1) and then transferred to 6 ml of the same medium and 
incubated at 37 °C for 24 h with shaking. Working stock cultures were kept as nutrient 
agar deep stabs (Table 1) which were made by inoculating with two stabs from the ATCC 
medium #17 cultures and incubated at 37 °C until growth was evident along the stab lines. 
Two stock tubes were kept at 4 °C for one month; one was kept to inoculate the next set of 
stock tubes and the other was used to inoculate cultures for protein purification. A 
glycerol-enriched stock culture was also generated by growing an overnight 37 °C culture 
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in nutrient broth (5 ml final volume). After incubation, glycerol was added to 15% final 
concentration and 0.5 ml aliquots were stored at -80 °C in screw top microfuge tubes. 
Table 1. Growth Media Formulations 
ATCC#l7 
Ingredient Amount added per liter 
Skim milk 100 g 
Tomato juice 100ml 
Yeast extract 5.0 g 
Tomato juice was filtered through #1 Whatman paper and left overnight at 4 °C then titrated 
to pH 7 .0 before use. 
PYTG Medium for E. faecalis 
Ingredient g per liter Final Concentration 
(%) 
K2HP04 5.0 0.5 
Yeast extract . 10.0 1.0 
Tryptone 10.0 1.0 
*Glucose 1.0 0.1 
pH 7.0, *Glucose is autoclaved separately, then added to the medium at time of 
inoculation. Agar tubes contained 2% w/v agar. 
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Ingredient 
2 Acid hydrolyzed casein·· 
2Enzyme hydrolyzed casein 
3Glucose 
Sodium thioglycolate 
DL-tryptophan 
L-cysteine 
Adenine 
Guanine 
Uracil 
Nicotinic acid 
Riboflavin 
Pyridoxine.HCI 
Thiamine.HCI 
Calcium pantothenate 
Folic acid 
Biotin 
I (51) 
Lipoic Acid Deficient Medium 1 
Amount added per liter final 
200 ml (10.0 g) 
200 ml (7 .5 g) 
3.0 g 
5.0 g 
100mg 
200mg 
200mg 
25mg 
25mg 
25mg 
5mg 
1 mg 
1 mg 
1 mg 
I mg 
10 µg 
I µg 
5 ml 
2Commercial acid and enzyme hydrolyzed casein (United States Biochemical) were 
treated as follows: 222.2 g of acid hydrolyzed and 167 g of enzymatic hydrolyzed 
casein were dissolved separately in 4 liter each of water. Then 50 g of activated 
charcoal was added to each and stirred for 30 min. The solutions were filtered through 
Whatman #1 paper and 100 ml of glacial acetic acid and 50 g more activated charcoal 
were added. The solutions were stirred for 30 min, filtered, diluted to 4.5 liters and 
stored at 4 °C. 
3Put glucose into solution and autoclave separately 
4Salts B (29): 10 g MgS04°7H20, 0.5 g NaCl, 0.5 g FeS04•7H20, and 0.38 g 
MnSQ4.H20 in 250 ml final volume. 
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C. Protein Concentration Determination 
1. Pierce BCA Assay 
This assay was done as per manufacturer's instructions using BSA as a standard. On 
occasion the assay was performed using a microwave oven as incubation heat source with 
a 100 ml beaker of water included as a heat sink as per Aikins and Taun (52). 
2. Bradford Assay 
This assay was used as per Bollag and Edelstein (53) with BSA as a standard. 
3. Spectrophotometric Assay 
This assay was done as per Kalb and Bemlohr (54). The spectrophotometer was zeroed 
with sample buffer. Absorbance values were determined with 2 or 3 different dilutions. 
Protein concentration was determined using the empirical formula 
µg/ml = (183 x A230) - (75.8 x A260) 
for samples with an A230 less than 1.5. 
D. Sample Concentration 
1. Ultrafiltration 
To concentrate protein prior to column chromatography the method of choice was 
usually ultrafiltration using a device such as Micro-con®, Centri-con® or Centri-prep® 
from Amicon. Before use, these were treated with 10% polyethyleneglycol (PEG) as 
recommended by the manufacturer to reduce protein loss on the membrane. This method 
was also used to desalt samples or change the buffer. 
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The protein solution was put into the device and centrifuged as per manufacturer's 
instructions. For desalting or buffer exchange the solution was diluted with new buffer 
and centrifuged 4-5 times. The resulting solution was recovered as per manufacturer's 
instructions. 
2. TCA :precipitation 
To concentrate protein samples for SDS-PAGE, 100% (w/v) TCA was added to a 
final concentration of 10% TCA. The mixture was vortexed for 10 s, set on ice for 30 min, 
and the resulting precipitate was collected by centrifugation at 1000 x g for 5 min. The 
supernatant solution was poured off, the pellets washed in acetone and then air dried. The 
dried pellets were dissolved in a minimal amount of SDS sample buffer and boiled prior to 
electrophoresis (55). 
3. Phenol/Ether precipitation 
TCA precipitation often leaves an acidified pellet unsuitable for SDS-P AGE. To 
overcome this, phenol/ether precipitation was performed as described by Sauve et al. (56). 
An equal volume of water-saturated phenol was added to dilute protein samples which were 
vortexed for 20 s and centrifuged at 12,000 x g for 5 min. The upper phase was discarded 
and the lower phase was extracted twice with 2 volumes of ether. The resulting aqueous 
phase was dried in a Speed Vac. The dried samples were redissolved in SDS-PAGE 
sample buffer and boiled prior to electrophoresis. 
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4. Speed Vac 
If the volume reduction required was small and salt concentration was not a 
concern, samples were concentrated in a Speed Vac as per manufacturer's instructions, 
being careful to not process to dryness unless desired. 
E. Assays 
The natural substrate of lipoamidase is lipoic acid attached to the E-amino group of 
lysine residues of proteins; lipoamidase can also cleave small synthetic molecules 
containing lipoic acid in an amide or ester linkage. Three lipoamidase assays were used: 
1) a PDH based assay (2) which measures lipoamidase activity by determining the 
decrease in PDH activity due to lipoic acid removal. The assay will be referred 
to as the PDH inactivation assay. 
2) a LA- pABA hydrolysis assay (57) which measures pABA released. 
3) a lipoyl domain inactivation assay which measures the release of lipoic acid from 
a human lipoyl domain peptide. Lipoamidase reduces the ability of a 
recombinant lipoyl domain to participate in a coupled oxidation reduction 
reaction with exogenous E3 subunit of the a-keto acid dehydrogenases 
(dihydrolipoyl dehydrogenase) and DTh1B (58). The assay will be referred to 
as the LipDom inactivation assay. 
F. PDH Assav 
1. Principle 
The PDH assay used is a modified version of the dismutation assay originally 
described by Korkes et al. (59); it is modified as described by Reed et al. (2). In this assay 
acetyl-CoA generated by PDH from pyruvate is converted to acetyl-phosphate by 
phosphotransacetylase. The acetyl-phosphate is then non-enzymatically converted to an 
acetyl-hydroxamic-Fe complex which is quantitated by measuring absorbance at 540 nm. 
Lactate dehydrogenase is included to regenerate NAD+ (Fig. II-1). One unit of PDH 
activity generates 1 µmole of acetyl-phosphate per h at 37 °C. 
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Figure 11-1. PDH Assay Reaction Scheme. Reaction 1 is catalyzed by lipoylated 
PDH (holoPDH), reaction 2 is catalyzed by phosphotransacetylase (PTA), reaction 3 is 
catalyzed by lactate dehydrogenase (LDH). 
The generation of acetyl-CoA depends on the presence of all PDH cofactors 
including protein bound lipoic acid. Using a two stage approach, the assay described can 
determine the activity of enzymes which attach lipoic acid to the E2 with a resulting increase 
in PDH activity or determine the activity of enzymes which remove lipoic acid with a 
resulting decrease in PDH activity. 
To assay for lipoic acid attachment by the lipoic acid activating (lipoyl ligase) 
system the first stage of the assay utilizes apoPDH, lipoic acid and ATP as substrates. The 
decarboxy lation cofactor TPP is also added in stage one to insure it is bound to PD H E 1. 
In the second stage pyruvate is added as substrate for the newly activated PDH and 
phosphate is added as substrate for PT A. NAD+ and CoA are added as a cofactors. CoA is 
regenerated by reaction 2 and NAD+ is regenerated by reaction 3 (Fig. II-1) (even though 
amounts are added to assure saturating quantity). This is referred to as the apoPDH 
activation assay. 
To assay for lipoic acid removal by lipoamidase the first stage of the assay utilizes 
holoPDH as substrate. Pyruvate and CoA and NAD+ are added in the second stage as 
substrates for any active PDH remaining. This is referred to as the PDH inactivation assay. 
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2. Reagents for apoPDH Activation Assay 
Stage One 
0.01 ml of 1.0 mg/ml DL-lipoic acid (0.005 µmole) 
0.01 ml of 0.96 mg/ml TPP (0.02 µmole) 
0.01 ml of 1.0 mg/ml ATP (0.02 µmole) 
0.01 ml of 9.6 mg/ml MgS04 (0.8 µmole) 
0.006 ml of 1.0 M potassium phosphate buffer, pH 7.0 (6.0 µmole) 
0.004 ml of 12.0 mg/ml cysteine (1.0 µmole) [fresh daily] 
apoPDH (E. faecalis) 
an activating system preparation 
H20 to 0.25 ml final volume 
Stage Two 
0.25 ml complete stage one reaction mixture 
0.1 ml of 1.0 M potassium phosphate buffer, pH 7 .0 ( 100 µmole) 
0.8 unit phosphotransacetylase (PT A) (Sigma P-2669) 
9 .6 units of lactate dehydrogenase (LDH) (Sigma L-2881) 
0.1 ml of supplement containing CoA (0.1 µmole), NAD+ (0.23 µmole) and 
cysteine (6.4 µmole) [fresh daily] 
H20 to 1.0 ml (with 0.05 ml of pyruvate) 
The reaction is initiated with the addition of 0.05 ml of 1.0 M potassium pyruvate 
(50 µmole) 
Color Development Reagents 
1.0 ml of 0.1 M potassium citrate buffer, pH 5.4 
1.0 ml of pH 6.2 NH20H (4.0 M NH20H brought to pH 6.2 by addition of 3.5 M 
NaOH) [fresh daily] 
3.0 ml of Hoagland reagent (prepared by adding 30.0 ml of concentrated HCl, 50 g 
of FeCl3 and 25.0 g of trichloroacetic acid to 470 ml of H20). 
3. Procedure for the apoPDH Activation Assay 
Stage one is initiated with the addition of apoPDH and the mixture is vortexed and 
.incubated at 30 °C for various time depending on the activating system preparation. At the 
end of the stage one incubation the stage two components are added, the mixtures vortexed 
and incubated at 30 °C for 30 min. 
The colored product is developed by pipetting 0.950 ml of the stage two mixture 
into a 13 X 100 mm test tube containing 1.0 ml of 0.1 M potassium citrate buffer pH 5.4 
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and 1.0 ml of fresh pH 6.2 NH20H. The tubes are vortexed and incubated at room 
temperature for 10 min. Then 3 .0 ml of Hoagland reagent is added and the tubes are 
vortexed and then centrifuged at 1000 x g for 5 min to remove precipitated protein. The 
absorbance of the supernatant solution is then determined at 540 nm against a blank 
containing all components except the activating system. The amount of acetyl phosphate is 
determined by calculation based on a standard curve of succinic anhydride (60) (Fig. II-2). 
Controls typically include apoPDH without activating system and activating system without 
apoPDH. 
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Figure 11-2. Standard Curve for Acyl Phosphate. This curve was generated with 
succinic anhydride (60) in 0.02 M potassium phosphate buffer, pH 7.0 in 0.95 ml total 
volume then treated as described in the color development procedure. Succinic anhydride 
yields 80% of the absorbance of acyl phosphates. This curve has been corrected by 20% 
from the succinic anhydride values as per (60). The equation for the linear regression line 
determined from the data is:· y = -0.031 + 0.208x. R = 1. 
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4. Reagents for the PDH Inactivation Assay 
Stage One 
0.006 ml of 1.0 M potassium phosphate buffer, pH 7.0 (6.0 µmole) 
3-5 units of holoPDH ( one unit= 1 µmole of acyl-phosphate I hour of incubation). 
up to 0.094 ml of a lipoamidase preparation 
H20 to 0.20 ml final volume 
Stage Two 
0.20 ml of stage one reaction 
0.01 ml of 0.96 mg/ml TPP (0.02 µmole) 
0.01 ml of 9.6 mg/ml MgSO~ (0.8 µmole) 
0.004 ml of 12.0 mg/ml cysteine (1.0 µmole) [fresh daily] 
0.1 ml of 1.0 M potassium phosphate buffer, pH 7.0 (100 µmole) 
0.8 unit Sigma PTA 
9.6 units of Sigma LDH 
0.10 ml of supplement containing CoA (0.1 µmole), NAD+ (0.23 µmole) and 
cysteine (6.4 µmole) [fresh daily] 
H20 to 0.95 ml (with 0.05 ml of pyruvate) 
The reaction is initiated with 0.05 ml of 1.0 M potassium pyruvate (50 µmole) 
5. Procedure for PDH Inactivation Oipoamidase assay) 
Stage one is initiated with the addition of holoPDH and the mixture is vortexed and 
incubated at 30 °C for various times depending on the lipoamidase preparation (1-3 hours). 
At the end of stage one the stage two components are added and the mixtures are vortexed 
and incubated at 30 °C for 30 min. Color development is identical to that described in the 
procedure for apoPDH activation. Controls typically include holoPDH alone and 
lipoamidase alone. 
G. Pyruvate Dehydrogenase Inactivation I Reactivation Assay 
The PDH inactivation assay demonstrates a "loss of function" which may have 
many causes including, but not limited to, regulation of PDH by product inhibition, 
cleavage of the hinge region of E2 subunit or other locations, disruption of PDH subunit 
association, inhibition of assay accessory enzymes PT A or LDH, and utilization of assay 
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components by other enzymes. Therefore the only way to be certain that an observed loss 
of PDH activity is due to removal of lipoic acid by lipoamidase is to reattach lipoic acid and 
observe an increase in PDH activity or reactivation. 
Two methods are used to separate PDH from lipoamidase before reactivation. The 
sample is either centrifuged at 144,000 x g for 1 h to pellet the PDH or filtered through a 
100,000 MW cutoff centrifugal ultrafiltration device which retains PDH but not 
lipoamidase. 
For each lipoamidase fraction to be assayed 3-5 units of holoPDH in 0.1 ml; 0.05 
ml lipoamidase fraction; 0.05 ml of KP04 buffer, pH 7; and 0.05 ml H20 are combined in a 
1.5 ml microfuge tube, mixed and incubated at 30 °C for 1 h. A control containing an 
additional 0.05 ml of H20 in the place of the lipoamidase fraction is also included. At the 
end of 1 h incubation the PDH is separated from the lipoamidase by either 
ultracentrifugation or ultrafiltration. 
When ultracentrifugation is used, each 0.25 ml sample is centrifuged at 144,000 x g 
for one h. The pellet is then dissolved in 0.11 ml of KP04 buffer pH 7, two aliquots of 
0.05 ml each are put into 1.5 ml microfuge tubes and the stage one reagents are added. To 
one tube 0.1 ml of activating system is added and to the other 0.1 ml H20 is added.· These 
are incubated at 30 °C for 30 min at which time the stage two reagents are added and the 
PDH assay is completed as previously described. 
When ultrafiltration is used, each 0.25 ml sample is placed into a passivated Micro-
Con® 100 and centrifuged until all of the solution that can has passed through the filter, the 
concentrate is then recovered and diluted to 0.11 ml. Two aliquots of 0.05 ml are removed 
and placed into 1.5 ml microfuge tubes and treated as described for 144,000 x g treatment. 
Micro-Con® devices are passivated by soaking in 5% polyethylene glycol for 30 min and 
then washing with H20 before use. 
Controls include holoPDH without lipoamidase as a negative control and activating 
system plus apoPDH as a positive control for the activating system. 
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H. LA-pABA Hydrolysis Assay 
1. Synthesis of LA-pABA 
LA-pABA was synthesiied from DL-lipoic acid and Na-pABA (sodium para-amino 
benzoic acid) as per (43). Lipoic acid (5.0 mmole, 1.1 g) and triethylamine (5.0 mmole, 
0.51 g) were dissolved in 10.0 ml of THF and chilled in an ice/salt bath. 
Isobutylchloroformate (5.0 mmole, 0.68 g) was added dropwise with stirring. After 10 
min stirring, p-ABA (5.0 mmole, 0.76 g dissolved in 5.0 ml of 1.0 M NaOH) was added 
and the mixture stirred overnight at room temperature. The solution was then extracted 
twice with 40.0 ml of benzene to remove unreacted p-ABA. The slightly yellow upper 
layer was discarded and the deeply yellow lower phase was diluted to 50.0 ml with H20. 
Then 12.0 ml of 0.5 M HCI was added to precipitate LA-pABA. The resulting milky 
yellow mixture was filtered through Whatman #1 filter paper in a Bilchner funnel. The pale 
yellow precipitate left on the filter was washed with a mixture of ethanol:H20:glacial acetic 
acid (45:45:10) to remove unreacted pABA. The washings were repeated until the filtrate 
was relatively free of pABA as determined by the Bratton-Marshall reaction 1 (61). 
Washing was done with 15 or 30 ml at a time for a total of 800 ml. 
After determining the filtrate was relatively free of pABA, the yellow LA-pABA 
precipitate was then washed with H20 until the pH was -7.0. This took about 2,500 ml. 
The compound was then dried over desiccant for - 60 h. yielding 1.13 g of dry material 
(-65%yield). 
The Bratton-Marshall reaction was performed by adding 1.0 ml of 0.1 % Na nitrite to l 0.0 ml of 
the filtrate, mixing, and incubating 3 min at room temperature, then 1.0 ml of 0.5% ammonium sulfamate 
was added and the solution was mixed and incubated 3 min at room temperature, then 1.0 ml of 0.1 % 
NEDD (N-1-napthylethylenediamine) was added and the solution was mixed and incubated 3 min at room 
temperature. The resulting pABA-NEDD conjugate was quantitated by measuring absorbance at 550 nm. 
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2. Assay Principle 
Lipoamidase cleaves LA-pABA to yield lipoic acid and pABA (62), pABA is then 
quantitated by coupling to NEDD by the Bratton-Marshall reaction (61) and measuring 
absorbance at 550 nm against a reagent blank (Fig. II-4). 
3. Assay Procedure 
Reagents 
up to 0.5 ml of enzyme fraction 
0.25 ml of 20 mM potassium phosphate buffer pH 7.0 . 
0.25 ml of 600 µM LA-pABA 
H20 to 1.0 ml as required 
The assay for lipoamidase is performed as per Garganta and Wolfe (43) by 
combining enzyme fraction with buffer and water, initiating the reaction with LA-pABA, 
and incubating tubes at 30 or 37 °C for at least one h. At the end of the incubation the 
reaction is stopped by acidification with 0.10 ml of 100% TCA. Precipitated protein is 
removed by centrifugation at 2000 x g for 10 min. An aliquot of the supernatant solution 
(typically 0.95 ml) is removed to a 10 x 75 mm test tube and 0.1 ml of 0.1 % Na nitrite is 
added. This is mixed well and incubated at room temperature for 3 min and then 0.1 ml of 
0.5% ammonium sulfamate is added and the tubes are mixed and incubated at room 
temperature for 3 min. Then 0.1 ml of 0.1 % NEDD is added, the solution is mixed and 
incubated at room temperature for 3 min, then vortexed for at least 10 s to remove gas 
bubbles which interfere with absorbance measurements. Each tube is then measured at 540 
nm against a reagent blank. Controls include reagents only, pABA alone as a positive 
control, LA-pABA alone and sometimes the enzyme fraction of interest alone. The amount 
of pABA released from LA-pABA is determined from the equation generated from a 
standard curve for pABA as described (Fig. II-3). The assay scheme is diagrammed in 
Fig. II-4. 
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Figure 11-3. Standard Curve for pABA. Aliquots of pABA were added to 0.25 ml 
of 20 mM potassium phosphate buffer, pH 7 .0 and H20 to 1.0 ml final volume and then 
color developed as described. Linear regression analysis gives the equation y = 0.030x 
+0.018 with a regression coefficient of R = 0.999. 
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Figure 11-4. LA-pABA Cleavage Assay Scheme. LA-pABA is cleaved by 
lipoamidase to yield lipoic acid and pABA. pABA is conjugated to NEDD through 
consecutive addition of TCA, sodium nitrite, ammonium sulfamate and NEDD. The pABA 
-NEDD conjugate is determined at 550 and quantitated using a pABA standard curve. 
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I. E3/DTNB Recycling Assay ( Lip Dom Assay) 
1. Principle 
The procedures for this assay and E. coli carrying the pGEX-2T plasmid with the 
GST-lipoyl domain fusion protein were kindly provided by Dr. Thomas Roche, Kansas 
State University. The lipoyl domain used consists of amino acids 1-98 of the human PDH 
E2 subunit fused to glutathione S-transferase (GST, Pharmacia). It is supplied in a pGEX-
2T plasmid harbored and produced in E.coli host strain JM-109. The growth, purification 
procedures and assay procedures are essentially as described by Liu et al. (63). The 
procedure measures the reaction of dihydrolipoyl moieties with DTNB to generate colored 
thionitrobenzoate (TNB) in a time course assay. The sensitivity of the assay is enhanced 
by recycling lipoyl domains by E3 (Fig. II-5). Since lipoyl domain activity is dependent on 
the presence of bound lipoic acid and each lipoyl domain contains only one lipoic acid this 
assay can measure lipoamidase activity as a decrease in TNB production. Neither free 
lipoic acid nor lipoyl-lysine are as efficiently recycled by E3 as complete lipoyl domain (64) 
(Fig. II-6). However lipoyl-lysine does have -25 % the acti_vity of lipoyl domain. 
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Figure 11-5. Reaction Scheme E3/DTNB Recycle Assay (LipDom 
inactivation). Reduced lipoyl domain is oxidized by DTNB with the generation of 2 
molecules of TNB. The oxidized lipoyl domain is then reduced by the FADH2 associated 
with the PDH E3 subunit and recycled for further reaction with DTNB. The E3 FAD+ is 
reduced by solution NADH completing one cycle. 
32 
0.6 
C) 
E 
C: 0.5 
.E 
..._ 
CJ) 
0 0.4 E g 
>, 
- 0.3 ·;; 
:;:: 
0 
<( 
0 0.2 ;;:::: 
·c:s 
CJ) 
a. 
en 
>, 0.1 
0 
a. 
:.:::i 
0 
0 
_[Y"" 
--
o LipDom 
-a- -LipLys 
__.. · - LipAcid 
-- ... -0 
.--- --.. ----
.. - - 4 
------· 
10 20 30 40 50 
Micromoles of Lipoyl 
Figure 11-6. Lipoyl Specific Activity in the E3/DTNB Recycling Assay 
with Different Lipoyl Moieties. The assay was performed as described by initiating 
the reaction with the indicated amounts of lipoyl moiety. LipDom is lipoylated recombinant 
amino acid 1-98 of human E2 fused to glutathione S-transferase, LipLys is lipoic acid 
linked to the E-NH2 of lysine, LipAcid is free lipoic acid. Data points are the average of 
three replicates of TNB production measured over 1 min. 
2. Lipoyl Domain Production 
E.coli harboring the lipoyl domain plasmid was grown to an OD600 of 0.7-0.8 at 37 
~C in LB medium containing 0.01 % glucose, 1 rnM ampicillin and 0.2 rnM lipoic acid and 
then induced to express the fusion protein by the addition of IPTG to 1 rnM. The cells 
were incubated for an additional 5.5 hand then harvested by centrifugation (10,000 x g at 4 
~C for 10 min). The cell pellet was washed twice by resuspension in 50 rnM Tris buffer 
pH 8, containing 150 rnM NaCl and 10 rnM EDTA and pelleted at 10,000 x g. The pellet 
was weighed and then suspended in phosphate buffered saline, (PBS) pH 7 .2 containing 
1 % Triton X-100; 5 rnM EDT A; 1 µg/ml leupeptin; 1 µg/rnl aprotinin; and O .1 rnM PMSF 
at 10 ml of buffer per g cells. Lysozyme was added at 10 mg per g cell paste and the 
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mixture was stirred on ice for 30 min. The cell mixture was then sonicated at -50% full 
power with a Heat Systems Ultrasonics instrument for 10 x 1 min cycles with 1 min 
cooling in between. Cellular debris was pelleted and the lysate clarified by centrifugation 
at 10,000 x g at 4 °C for 5 min. GST activity of the fusion protein was determined by 
monitoring the formation of DNB-S-GSH from 1-chloro-2,4-dinitrobenzene (CDNB) and 
glutathione (GSH) as an increase in absorbance at 340 nm. 
The reaction mixture contained 0.890 - 0.899 ml of 0.1 M NaP04 , 50 µl of 20 rnM 
glutathione (GSH) and 50 µl of 20 mM CDNB in a 1 ml final volume (including GST-
LipDom). After mixing and measuring baseline absorbance at 340 nm, the reaction was 
initiated by adding 1-10 µl of the GST-LipDom preparation and monitoring A340• The total 
mg of GST was calculated using the molar extinction coefficient of DNB-S-GSH of 9.6 
mM· 1cm·1 to convert Li A340 to Li mmole. Assuming 1.0 mg of GST will produce DNB-S-
GSH at a rate of 0.014 mmole/min, the mg of GST can be calculated and the mg of lipoyl 
domain can be calculated based on a ratio of 3 mg GST: 1 mg lipoyl domain. 
GST activity 
GST total activity 
mgGST 
!::..Ax mmole•cm , L x La= mmole 
min 9.6 LA cm LE LE•min 
mmole x total LE= mmole ---> mmole = TA 
LE•min mm mm 
1 mg GST , TA = mg GST 
.014 TA 
Figure 11-7. Calculation of mg GST for Determination of Lipoyl Domain 
Produced. LE is volume of enzyme added to assay, LA is total volume of assay mix. TA 
is GST Total Activity. 
The lysate was then combined with GSH-Sepharose 4B gel (5 mg of GST per ml 
of gel) which had been equilibrated with 10 bed volumes of PBS, pH 7 .2 containing .1.0% 
Triton X-100. The gel-protein mixture was shaken at room temperature for 30 min, 
centrifuged at 1,000 x g and the supernatant solution carefully decanted and assayed for 
GST activity. If activity was present, the supernatant solution was saved at -80 °C and the 
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remaining GST-LipDom purified later. The gel was then washed 8 times with 2 volumes 
of PBS, pH 7.2 containing 1.0% Triton X-100 followed by 3 washes of 2 volumes of 50 
mM Tris, pH 8.0 containing 150 mM NaCl. The Tris washes were continued until A']Jl() 
was below 0.001. The gel was then transferred to a glass column, allowed to settle and the 
buffer drained down to the top of the column. At this point 3 volumes of 50 mM Tris pH 
8.0 containing 150 mM NaCl and 5 mM GSH were carefully added to the top of the 
column and any disturbed gel allowed to settle. The column was then eluted at -1 ml/min 
with monitoring at 280 nm. The protein peak was collected and then placed into Centri-
Prep® 30 ultrafiltration devices that had been pre-treated with PEG. The buffer was 
changed to 20 mM potassium phosphate buffer pH 7.0 containing 0.04 mg/ml EGTA, 0.01 
µg/µl leupeptin and 0.01 µg/µl aprotinin by repeated processing in the Centri-Prep® 30 and 
dilution in the new buffer. The solution was brought to protein concentration of -15 
mg/ml. The column was regenerated by washing with 3 column volumes of 50 mM Tris 
pH 8.0 containing 150 mM NaCl and 5 rnM GSH, followed by 3 column volumes of PBS, 
pH 7.2 containing 2.85 M NaCl and 1 rnM EDTA. The gel was stored in 10% ethanol at 4 
~C. The concentrated GST-LipDom preparation was distributed in 0.1 ml aliquots and 
stored at -80 °C and hereafter referred to simply as LipDom. 
3. E3/DTNB Assay Procedure 
Reaction Mix 
50 µl of 0.2 M sodium phosphate buffer, pH 7.4, containing 2 mM EDTA 
20 µl of aqueous solution of 3 rnM NADH and 1 mM NAD+ 
20 µl of 1.5 mM DTNB in 50 rnM sodium phosphate buffer, pH 7.4 
0.1- 0.5 µg of E3 (Lipoamide dehydrogenase Sigma L-2002) 
50- 90 µgGST-LipDom (10-40 µM final concentration) 
H20 to a final volume of 0.2 ml (including the GST-LipDom). 
The spectrophotometer is zeroed with the reaction mix without GST-LipDom at 405 
nm. The reaction is initiated by the addition of lipoyl domain and the progress of TNB 
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formation followed for at least 45 s. The molar extinction coefficient for TNB is 27 .2 
rru\1· 1cm·1• 
To measure lipoamidase activity, -225 µg lipoyl domain was mixed with either 
lipoamidase fraction or equivalent volume of buffer as control in a total volume of 100 µl, 
then 15 µl was removed and added to the E3/DTNB assay mix to initiate the reaction. The 
formation of TNB was followed for at least 45 s at 405 nm in triplicate to determine t=O 
activity. This procedure was repeated for all the treatments of a given sample. The 
remaining lipoamidase fraction I lipoyl domain mixture was incubated at 37 °C for various 
times. At the end of the incubation time the aliquots of the samples were again assayed in 
triplicate (by initiating the E3/DTNB reaction with 15 µl incubation mixture). The rate data 
obtained was analyzed by using a two sample for means t-test for a significant difference 
between the t=O and t=X rates. A significant difference in reaction rates between t=O and 
t=X indicates lipoamidase removal of lipoic acid from the GST-LipDom. A treatment mix 
containing only lipoyl domain and buffer was included as positive control. 
J. Purification 
E. faecalis homogenates contain PDH, the lipoic acid activating system and 
lipoamidase. The first objective of the purification was to separate these three systems. 
Reed et al. (8) reported a procedure which separated the three components (Fig. II-8) using 
protamine sulfate to precipitate the PDH, followed by ammonium sulfate fractionation 
which separated the activating system from lipoamidase. I used this procedure unaltered. 
PDH typically precipitated with the addition of 0.16 - 0.20 volumes of 2% protamine 
sulfate. Addition of 0.35 g of solid ammonium sulfate per ml of solution typically 
completely precipitated lipoamidase, leaving the activating system in solution. 
The partial purification of lipoamidase through DEAE column chromatography was 
done according to the protocol of Suzuki and Reed (31) and is outlined in Fig II-9. 
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E. faeca/is wet cells 
Suspend in 0.02 M KP04 pH 7.0 at 3.3 ml/g 
Divide into <50 ml portions 
Sonicate 30 min. ea. 
Centrifuge 30 min @ 47.8k x g 
------------
--~•~ SONS 
Discard Dilute to 20.0 mg/ml protein 
Adjust pH to 6.0 w/ 1 N acetic acid 
-----'l)I,• pH6S0NS 
Add 0.10 vol. of 2% protamine sulfate (pH 6.2) 
Stir 15' longer 
Centrifuge 11 min @ 4000 x g 
0.1PSP oll( )I, 0.1PSS 
Discard if PDH activity in supernatant 
solution does not decrease (Assay forl PDH activity) 
Repeat additions of 0.02 vol aliquots of 2% protamine 
sulfate and centr'fugation until PDH activity pelleted 
Stir 15' longer 
__________ __. ..... C __ e=n .... tr __ if __ u_.e;:;...-:a,30 min @ 4000 x g 
0.12-XPSP .... oll(---
--..;:ii)II,~ 0 .12-XPSS 
__ , __ 
Save pellet(s) corresponding to decreased 
PDH activity in supernatant solution, 
these contain PD H 
When PDH activity in supernatant solution is gone 
add 0.35 g of solid ammonium sulfate per 
AS1P ... 11111(---
Lipoamidase 
ml of PSS (slowly with stirring) 
---":>~ AS 1 S 
Activating System 
Figure 11-8. Flow Chart for Separation of PDH, Lipoamidase and the 
Lipoic Acid Activating System. II = supernatant solution, _I = pellet, dashed lines 
indicate operations which were repeated a variable number of times from batch to batch. 
PSP = protamine sulfate pellets, PSS = protamine sulfate supernatant solution, 0 .12-XPSP 
and PSS indicate successive fractions as 0.02 volume portions of protamine sulfate are 
added, AS lP = ammonium sulfate pellet, AS lS = ammonium sulfate supernatant solution. 
-4Fraction = fraction designation and that a sample is saved for assay. 
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Dissolve in 0.02 M potassium 
phosphate, pH 7.0 
I 
Dialyze against 0.02 M potassium 
phosphate, pH 7.0 
AS1DP ... 1111(1---
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Discard 
Figure 11-9. Flow-Chart for Lipoamidase Purification Through DEAE. 
~Fraction indicate fraction designation and that a sample is saved for assay. Fractions 
designations: ending in 'P' indicate pellets, "DP" indicate dialyzed pellets and "S" indicate 
supernatant solutions. 
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K. Chromatography 
1. DEAE column chromatography 
A 2.5 cm x 12 cm column ofWhatman DE-52 anion exchange resin was run using 
a Bio-Rad Econo pump, an Isco UA-5 detector and an Isco Foxy fraction collector. All 
operations were performed at 4 cc following the procedure of Suzuki and Reed (8) with the 
addition of a 0.5 M KCl column stripping step. The column was equilibrated in 20 mM 
potassium phosphate buffer, pH 7 .0. The sample was applied and washed onto the 
column with 80 ml of starting buffer at a flow rate of 1.0 ml/min and monitoring at 280 nm 
while collecting eluent in an Ehrlenmyer flask. The column was then eluted with a 
stepwise gradient of KCl in starting buffer, monitoring protein elution at 280 nm and 
collecting 5 ml fractions in 13 x 100 mm test tubes. The steps were 80 ml each of 0.1 M 
KCl, 0.15 M KCl and 0.5 M KCl. Some column runs were washed with 80 ml of starting 
buffer between KCI steps. Fractions containing protein were assayed for lipoamidase 
activity [by the PDH inactivation assay or the LA-pABA hydrolysis assay or the LipDom 
inactivation assay]. 
2. Hydroxylapatite column chromatography 
Bio-Rad HTP and HTP-II 5 ml Econo columns were connected to a Bio-Rad Econo 
chromatography system. All operations were performed at 4 cc. The columns were 
equilibrated in 10 mM sodium phosphate buffer pH 7 .2. Samples were applied to the 
column in 10 mM sodium phosphate, pH 6.8 and eluted in a gradient of 10-380 mM 
sodium phosphate, pH 6.8. Protein elution was monitored at 280 nm and fractions 
collected. The volume used for elution and fraction collection varied among column runs in 
order to optimize separation. Protein containing fractions were assayed for lipoamidase 
activity [as described for DEAE column chromatography]. 
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3. Dye affinity chromatography 
Sigma RDL-9 Dye Resin test kit columns (nine 2.5 ml bed volume columns each 
with a different dye attached to crosslinked beaded 4% agarose) were used. The dyes were 
Cibacron Blue 3GA (CBS), Reactive Green 5 (RGS-5), Reactive Brown 10 (RB 10-5), 
Reactive Blue 72 (RB72-5), Reactive Blue 4 (RB4-5), Reactive Yellow 86 (RY86-5), 
Reactive Yellow 3 (RY3-5), Reactive Red 120 (RR120-5) and Reactive Green 19 (RG19-
5). The Bio-Rad Econo System was used to pump, generate gradient, monitor and record 
elution A280 and collect fractions. All operations were performed at 4 °C. The columns 
were screened for lipoamidase retention as described below. The starting buffer was 20 
mM potassium phosphate pH 7.0 and elution was achieved with KCl in 20 mM potassium 
phosphate, pH 7 .0. The columns were equilibrated with 25 ml of starting buffer, and 
sample was loaded and washed on with another 25 ml of starting buffer at 0.8 m1/min 
while collecting the eluant in flasks. During screening the proteins were eluted in 1.5 M 
KCl in starting buffer while monitoring eluate at 280 nm and collecting 1.6 ml fractions. 
The flow-through and selected fractions were then assayed by the LA-pABA assay in 96 
well plates using 30 µmoles of LA-pABA and 0.15 ml sample in 0.2 ml total volume and 
scoring by a visual presence or absence of pink color. 
Later runs using columns which exhibited lipoamidase activity retention were eluted 
with linear gradients of 0-1.5 M KCl in starting buffer at 0.8 m1/min while monitoring at 
280 nm and collecting 1.6 ml fractions. Protein containing fractions were assayed for 
lipoamidase activity with the LA- pABA cleavage assay. 
4. Mono Q anion exchange chromatographv 
A Pharmacia FPLC HR 5/5 Mono Q column was used with an lsco model 2360 
gradient programmer, an LDC Analytical HPLC pump equipped with a pulse damper, an 
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Isco UA-5 detector and a Gilson model 203 fraction collector. All operations were 
performed at 4 °C. The column was equilibrated in BisTris, pH 7.0 ionic strength 0.01 
(I= 0.01) starting buffer. Samples were loaded in starting buffer at 0.5 ml/min. Fractions 
were eluted in a linear gradient of 0.0-0.5 M KCl in starting buffer. Protein elution was 
monitored at 280 nm and 0.5 ml fractions were collected. Protein containing fractions were 
assayed for lipoamidase activity with the LA-pABA cleavage assay and the LipDom 
inactivation assay. 
5. Hydrophobic interaction chromatography 
Two HIC columns were used: a Butyl Sepharose 4 Fast Flow, and an Octyl 
Sepharose 4 Fast Flow. Both columns were from a Hi Trap™ HIC Test Kit from 
Pharmacia Biotech. The columns were equilibrated in 20 rru\1 potassium phosphate buffer, 
pH 7.0 with 1 M KCl (starting buffer). The flow rate was 1.0 ml/min using a Bio-Rad 
Econo System for gradient formation, pumping, UV elution monitoring at 280 nm and 
fraction collection. The gradient involved a decrease in KCl from 1.0 M to OM. Samples 
were loaded in 1.0 M KCl, 1 ml fractions collected and protein containing peaks assayed 
for lipoamidase activity with the LA-pABA hydrolysis assay and the LipDom inactivation 
assay. 
L. Electrophoretic Methods 
1. General 
Standards used included Bio-Rad High Molecular weight standards (45-200 kDa), 
Bio-Rad Low Molecular weight standards (14-97 kDa), Sigma Mark VII standards (14-66 
kDa) and Bio-Rad Kaleidoscope Pre-Stained standards ( 6.9-202 kDa). 
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Gels were stained with Coomassie Blue (53) or with Bio-Rad Silver Stain Plus as 
per supplier's instructions. When Coomassie Blue staining was unsatisfactory, gels were 
completely destained in methanol:acetic acid:H20 ( 4: 1 :5), washed extensively in H20, and 
silver stained, omitting the silver fixative and subsequent wash step. Silver-stained gels 
exhibiting very high background were treated with a silver destaining solution as described 
by Bio-Rad until the background was satisfactory. If destaining was complete or bands 
disappeared, the gels were restained. 
Analysis of gel band patterns was done using Bio-Rad Molecular Analyst software 
from gel images generated on a Bio-Rad densitometer 
2. Phast System 
Samples were often analyzed by SDS-PAGE on a Pharmacia Phast System™. 
Samples were prepared as recommended by Pharmacia. Gel formats used included 12.5% 
homogeneous, and 10-15% Gradient. Separation program conditions were essentially 
those recommended by the manufacturer. Coomassie Blue staining was done in the Phast 
System™ staining unit as per Pharmacia' s instructions. Silver staining was done manually 
in a Petri dish with Silver Stain Plus reagents from Bio-Rad as per manufacturer's 
instructions using 1/5 the amount of reagents suggested for a mini gel. 
3. Mini Gels 
SDS and native PAGE gels were run with a Bio-Rad Mini Protean II apparatus. 
Buffers and solutions were as per Bollag and Edelstein (53). 
For preparative native PAGE gels, multiple lanes were loaded with the fraction of 
interest. After the separation was performed the gel sandwich was carefully disassembled 
leaving the gel on one of the glass plates. The gel was then cut parallel to the direction of 
migration into sections for analysis. The sections were left together on the plate and 
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realigned as if the gel had not been cut. The section to be assayed for enzyme activity was 
then sliced into eleven or twelve pieces perpendicular to the direction of migration with a 
multiple razor blade gel slicer. Care was taken to make slice marks in the edge of the of gel 
section to be stained in order to correlate banding pattern to activity in slices (Fig. II-8). 
Cut Cut Cut 
Figure 11-10. Diagram of Preparative Native PAGE Gel. The "Stain" section 
was silver stained to give a native PAGE banding profile. The "Assay" section was utilized 
to obtain lipoamidase activity data from the electrophoretically separated proteins. The 
"SDS-PAGE" section was used obtain an SDS-PAGE profile of native PAGE separated 
proteins. Note slice marks left in "Stain" section to allow correlation of activity to banding 
pattern. 
The gel slices to be assayed were treated in one of two ways. Each gel slice was 
put into 0.02 M potassium phosphate, pH 7 .0 in a microfuge tube, ground with a pestle, 
soaked overnight at 4 °C, then centrifuged at full speed in a Beckman table top microfuge 
and the supernatant solution removed and added to assay mixture. The other method of 
treatment used electroelution with either a Bio-Rad electroeluter or a homemade device. 
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lvf. Preparation of Protein for Microsequencing Using SDS-PAGE and Electro-transfer to 
PVDF 
1. Solutions 
SDS-PAGE stock solutions 
4x separating gel buffer - 1.5 M Tris, pH 8.8 with 0.4% SDS 
4x stack gel buffer - 0.5 M Tris, pH 6.8 with 0.4% SDS 
30% acrylamide - (30.8%T, 2.6%C) 
10 mM sodium thioglycolate 
Tank buffer - 25 mM Tris, 192 mM glycine and 0.1 % SDS 
10% ammonium persulfate 
10% SDS 
4X sample buffer (stored frozen) 20% glycerol, 28.8 mM 2-mercaptoethanol, 6% 
SDS, 0.005% bromophenol blue and 125 mM Tris, pH 6. 
Pre-run Buffer - 0.38 M Tris, 0.1 % SDS and 0.1 mM Na thioglycolate, pH 8.8 
Stack set buffer - 0.5 M Tris, 0.1 mM Na thioglycolate, 0.4% SDS, pH 8.8 
Stack set indicator - 0.008% bromophenol blue, 83% glycerol, 0.83% stack set 
buffer 
Semi-dry electroblotting stock solutions 
Transfer buffer [Bjerrum and Schafer-Nielsen (78)] 48 mM Tris, 39 mM glycine, 
20% methanol and 1.3 mM SDS (pH should be -8.2, if not the solution is remade). 
Coomassie Blue Staining Reagents 
G-250 Stain - 0.1 % Coomassie Blue G-250, 40% methanol and 1.0% acetic acid 
(filtered through a 0.45 µm filter). 
Destain - 50% methanol in HP 
2. Procedure 
Overview 
LeGendre et al., in "A Practical Guide to Protein and Peptide Purification for 
Microsequencing (pp74-100)" (55), identify N-terminal blockage that occurs during 
electrophoresis as a major problem in lowering N-terminal sequencing success. They 
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suggest pre-running the gel just prior to loading the sample. Promega, in "Protein Guide, 
Tips and Techniques" suggest polymerizing gels at least 4 h prior to sample loading and 
' adding thioglycolic acid to the upper gel buffer. The protocol used talces all of these 
precautions as well as adding thioglycolate to the pre-run buffer to remove any unreacted 
gel components which might react with the N-terminal of proteins loaded and run on the 
gel. 
Gel Preparation 
This protocol used a single buffer (separating gel buffer) for separating and 
stacking gel since the prerun with Na thioglycolate would abolish a normal buffer 
discontinuity. The separating gel solution was prepared without APS and 1EMED and 
degassed for 5 min under vacuum. TEMED and APS were added and the solution poured 
to within 2.0 cm of the top of the short plate, carefully overlaid with H20 and allowed to 
polymerize for one h. The water was then poured off and the top of the gel rinsed with 
water. Degassed 4% stacking gel solution was then added, the appropriate comb set in 
place, and the gel allowed to polymerize overnight at 4 °C. 
Prerun and pH Reset of Stacking Gel 
The gel was pre-run with pre-run buffer at 50 V for one hour at 4 °C to prevent 
artifactual N-terminal blockage of electrophoresed proteins. The samples to be run were 
mixed 2: 1 with sample buffer and boiled for 2 min. After the pre-run the buffer was 
poured out of the inner buffer chamber and the wells rinsed thoroughly with H20. The unit 
was reassembled and the inner buffer chamber was filled with Stack Set buffer. Stack Set 
indicator ( 10 µl) was put into each of the outside and a middle well and the unit was run at 
50 V until bromophenol blue reached the stacking/separating gel interface. 
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Sample Loading and Gel Run 
After resetting the stacking gel both buff er chambers were emptied and gel wells 
were thoroughly rinsed with H20. The buffer chambers were refilled with tank buffer and 
1.5 ml of 10 mM Na-thioglycolate was added to the upper tank and stirred. An outside 
lane was loaded with Kaleidoscope™ prestained standards. The samples were loaded and 
electrophoresed at 25 mA. 
Transfer, Staining and Band Recoverv 
While the gel was running a 5.5 X 8.0 cm piece of PVDF membrane was wet in 
100% methanol for a few seconds and then equilibrated for at least 15 min in transfer 
buffer. Two pieces of 5.5 X 8.0 cm Bio·Rad transfer filter paper were also soaked in 
transfer buffer. Electrophoresis was stopped when the dye front neared the bottom of the 
gel. The gel was removed from the electrophoresis unit and soaked for five min in 100 ml 
of transfer buffer. The transfer apparatus (Bio-Rad SD semi-dry) was assembled with gel 
in place according to manufacturer's instructions. After electroblotting at 15 V for 15 - 30 
min the current was stopped and the cathode plate was carefully lifted without disturbing 
the gel/membrane sandwich. Then the membrane was carefully separated from the gel at 
the end containing the pre-stained standards and an evaluation of the transfer was made. If 
the prestained standards were still in the gel the sandwich was resealed, the cathode 
replaced and the transfer continued. When the transfer was complete, the unit was 
disassembled and the membrane was rinsed with H20. The membrane was then soaked in 
100% methanol for a few s and placed into Coomassie Blue G-250 stain and incubated 
with orbital shaking. Protein bands typically appeared within one min. Longer staining 
time resulted in very high background. Moderate background was removed by soaking in 
destain solution until background was acceptable. The membrane was then rinsed 
thoroughly with H20 and the band of interest was cut out with a clean razor blade. The 
band alone was further rinsed with H20 to remove all traces of transfer, staining and 
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destaining buffers. The gels were also stained to visualize proteins left in the gel and to 
analyze transfer efficiency. 
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CHAPTER III 
RESULTS 
A. Overview 
The purpose of this work was to obtain pure lipoamidase. Since the Reed and 
Suzuki (8) procedure achieved a 61-fold purification with a 46% yield, I started by using 
their procedure. For protein that has been purified through the DEAE column fractionation, 
I sought additional purification by measuring specific activity and by determining the 
number of protein species using PAGE. 
Fractions from hydroxylapatite chromatography were obtained with lipoamidase 
activity and constitute -200-800 fold purification with three proteins present. The three 
proteins were sequenced and two of them were fragments of elongation factor Ts (EF-Ts). 
The third protein has similarities to three different dehydrogenase sequences and also a 
glucosidase. This protein also has an NAD+-binding domain. Ion exchange 
chromatography on a MonoQ anion exchange column and a CM cation exchange column 
did not further separate the three proteins. The three proteins were not resolved nor 
significantly purified by hydrophobic interaction chromatography, dye affinity 
chromatography or preparative native PAGE. Three different assays were employed over 
the course of purification with none of the assays found to be well suited for anlayzing the 
purification of lipoamidase. One of the standard assays for mammalian lipoamidase 
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( cleavage of Lipoyl-pABA to lipoic acid and pABA) is not specific for lipoamidase activity 
in E. faecalis. 
B. Initial Results 
I began purifying lipoamidase using the procedure of Reed and Suzuki (8) (Fig. II-
7). E. faecalis cells were broken by sonic oscillation and PDH was then precipitated with 
protamine sulfate. Lipoamidase and the activating system were separated by precipitating 
lipoamidase with ammonium sulfate. The lipoamidase was then purified with two more 
ammonium sulfate fractionation steps. The last step in the Reed and Suzuki purification of 
lipoamidase was a DEAE cellulose anion exchange column with a three step gradient 
consisting of sample application in 0.02 M KPO 4, a 0.10 M KCl in 0.02M KPO 4 elution, 
and a final elution with 0.15 M KCl in 0.02 M KP04• The lipoamidase activity, as 
followed by the PDH inactivation assay, eluted with the 0.15 M KCl step. I added a 0.50 
M KCl in 0.02 M KP04 wash following the 0.15 M KCl elution to clean the column. My 
first 3 purifications, done before early 1994, agreed with those of the Reed group in that 
lipoamidase activity eluted in the 0.15 M KCl fractions. SDS-PAGE with Coomassie Blue 
staining of pooled active fractions showed a major band at -36 kDa and at least 2 minor 
bands below 20 kDa (Fig. III-1). 
After April 1994, DEAE chromatography yielded A280 patterns which looked nearly 
identical (Fig. III-2) to previous patterns, but lipoamidase activity was found in both the 
0.15 M KCl eluant and in the 0.10 M KCl eluant. Difficulties with salt interference in the 
PDH inactivation assay led me to look for an assay which would be less sensitive to salt 
concentration. An assay using lipoic acid attached to p-amino benzoic acid (LA-pABA) as 
a substrate (see Ch. II) proved less sensitive to salt concentration than the PDH inactivation 
assay. With the new assay in hand, I proceeded with purification up through DEAE 
chromatography (elution profile not shown). When DEAE fractions were assayed the 
major LA-pABA cleaving activity was found in the 0.10 M KCI peak with less activity in 
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the 0.15 M KCl and some in the 0.5 M KCl wash. The active fractions in the 0.10 M KCl 
peak were combined, concentrated and then re-assayed along with previous fractions using 
the LA-pABA assay to calculate purification data (Table ill-1 ). 
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Figure 111-1. SOS-PAGE of Combined DEAE Fractions That Contain 
Lipoamidase. Fractions 31-33 from DEAE anion exchange chromatography were 
combined and concentrated by ultrafiltration and a portion subjected to SDS-PAGE as 
described in Materials and Methods. Lanes 1 and 4 are Bio-Rad High Molecular Weight 
Markers. Lane 2 is AS3DP fraction [see purification scheme, Fig. II-9] . Lane 3 is pooled 
active DEAE fractions 31 -33 which were dialyzed against 20 nu\11 potassium phosphate 
buffer, pH 7 .0 and concentrated. Minor protein bands clearly visible on the original gel are 
not visible on this reproduction but are indicated by arrows. The major band is -36 kDa 
and comprises >90% of total Coomassie Blue stained protein. Two minor bands are < 20 
kDa and comprise -5% each of total Coomassie stained protein. 
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Figure III-2. DEAE Column Chromatography. Post April, 1994 DEAE column 
run showing PDH inactivation activity in the 0.1 M KCl and 0.15 M KCl fractions. 
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Table 111-1. Lipoamidase Purification Table Based on LA-pABA cleavage 
assay. Crude extract is post sonication supernatant solution, pH 6.0 SONS is the pH 
adjusted extract, 0.2 Prot Sulf is the extract after PDH had been removed by protamine 
sulfate precipitation, ASIDP is the dissolved dialyzed pellet after the first ammonium 
sulfate precipitation, AS3DP is the dissolved dialyzed pellet after the third ammonium 
sulfate precipitation, DEAE is combined active fractions from the 0.10 M KCl eluate. 
Fraction Specific Activity % Yield Purification 
(nmole/min·mg) 
Crude extract 0.73 100.0 1.0 
pH 6.0 SONS 0.80 81.9 1.0 
0.2 Prot Sulf 3.01 59.1 4.1 
ASlDP 7.16 50.9 9.8 
AS3DP 5.41 15.7 7.4 
DEAE 22.00 7.7 30.2 
Reed and Suzuki (31) reported 61-fold purification with 46% yield through the DEAE step 
using the PDH inactivation assay. Using the LA-pABA assay I obtained only 30-fold 
purification and less than 10% yield from the most active of the two peaks from the DEAE 
step. Based on the poor purification and the presence of activity in multiple fractions, the 
0.10 M KCl fractions were assayed with the PDH inactivation assay to verify the presence 
of lipoamidase activity. There was no inactivation of PDH in the 0.10 M KCl pooled 
fraction but the 0.15 M KCl fractions inactivated PDH. Calculation of purification data 
using the PDH inactivation assay (Table III-2) showed a 58-fold purification and 10.5% 
yield from the 0.15 M KCl peak. This was closer to the Reed and Suzuki results. 
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Table 111-2. Lipoamidase Purification Table Based on the PDH Inactivation 
Assay. Not all fractions assayed using LA-pABA were assayed here. pH 6.0 SONS is 
the pH adjusted extract, AS lDP is the dissolved dialyzed pellet after the first ammonium 
sulfate precipitation, AS3DP is the dissolved dialyzed pellet after the third ammonium 
sulfate precipitation, DEAE is the combined active fractions from the 0.15 M KCl eluate. 
Fraction Specific Activity % Yield Purification 
(nmole/min·mg) 
pH 6.0 SONS 9.63 100.0 1.0 
ASlDP 66.46 47.9 6.9 
AS3DP 102.4 30.0 10.6 
DEAE 553.8 10.5 58 .0 
Further analysis verified the presence of lipoamidase activity in the 0.15 M KCl fraction; 
there was 89% inactivation of a holoPDH preparation and then a 72% recovery by 
incubation with an activating system preparation (Fig. III-3). 
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Figure 111-3. Inactivation of PDH by Lipoamidase with Reactivation. The 
"PDH" set was the positive PDH control in which only buffer was added during the stage 1 
and stage 2 incubations (see Materials and Methods). The "Inact" set was the PDH activity 
after incubation with 0.15 M KCI post-DEAE lipoamidase fraction. The "React" set was 
the PDH activity of an aliquot of the "Inact" set after incubation with activating system. 
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SDS-PAGE analysis (Fig. III-4) of the 0.15 M KCl fractions showed 6 bands with 
the most prominent at - 35 kDa (-56 %) the next at -32 kDa (-22%) and minor bands 
(-9% and 12%) smaller than 30 kDa. When the gel was first developed there were other 
very faint bands which either faded with storage or are too faint to be seen in the picture . 
.... 66 
Figure 111-4. Silver Stained SOS-PAGE of 0.15 M KCl DEAE Eluate 
Pooled Active Fractions. Lane 1 is 0.5µg of pooled active fractions from the 0.15 M 
KCI eluate which had been dialyzed against 20 mM potassium phosphate buffer pH 7 .0. 
Not all of the bands evident on the gel are visible in this picture but are represented by 
arrows. Lane 2 is Bio-Rad High Molecular Weight Markers. 
The next time a DEAE column was run I used the LipDom inactivation assay 
(E3/DTNB) acquired from Dr. Thomas Roche. I used the LA-pABA assay to do initial 
screens on column fractions and then used the LipDom inactivation assay to establish 
lipoamidase activity. LA-pABA cleavage activity was found in the 0.02 M KP04 fraction 
and in the 0.15 M KCl fractions. However the LipDom inactivation assay showed activity 
only in the 0.15 M KCl peak (Fig. III-5). Different results were obtained from subsequent 
DEAE columns in that LA-pABA cleavage activity was in the 0.02 M KP04, 0.10 M KCI, 
0.15 M KCl and the 0.50 M KCI eluant. These two runs differ from all previous ones in 
that LA-pABA cleavage and LipDom inactivation activity were found in both the 0.10 M 
and 0.15 M KCl eluants (Fig. III-6). 
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Figure 111-5. DEAE Chromatogram with LA-pABA Cleavage and LipDom 
Inactivation Activity. Solid bars represent LA-pABA cleavage activity as nmoles of 
pABA generated. LipDom inactivation activity is indicated by +/- LipDom, fraction 8 
reduced LipDom activity a statistically non-significant 4.6 nmole/min-mg (t-stat = 1.57), 
fraction 48 reduced LipDom activity a significant 14.0 nmole/min-mg (t-stat = 6.8, the t-
Critical for P=.05 is 2.9). 
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Figure 111-6. DEAE Chromatogram with LA-pABA and LipDom Cleaving 
Activity in 0.1 M KCI eluant. Bars represent LA-pABA cleavage activity as nmoles 
of pABA generated. LipDom inactivation is represented by +/-LipDom and plain text 
fraction numbers indicate fractions assayed for LipDom inactivation. The 0.02 M KCl 
eluate did not inactivate LipDom (t-stat = 0.04), fraction 64 inactivated LipDom a 
statistically significant 28.2 nmole/rnin-mg (t-stat = 8.49), and fraction 104 inactivated 
LipDom a statistically significant 14.5 nmole/min-mg (t-stat = 10.71, the t-Critical at 
P=.05 is 2.9). 
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I found that screening DEAE column fractions with the PDH inactivation assay 
often gave false positives because the salt concentration of the elution buffer was high 
enough to inhibit PDH activity. Therefore I began using LA-pABA to assay column 
fractions because it is a relatively fast and easy assay and is not affected by high salt 
concentration. However it is not very specific as some fractions with high LA-pABA 
cleaving activity are unable to inactivate PDH. Therefore the assay was used for initial 
screening of fractions and the positive ones were then assayed with another method to 
verify lipoamidase activity. The LipDom inactivation assay is not sensitive to the salt 
concentration and was often used to verify lipoarnidase activity. In later runs LipDom 
inactivation (lipoarnidase) was found not only in the 0.15 M KCl eluant but also in the 0.10 
M KCl fraction. 
C. Native PAGE 
Attempts were made using non-denaturing polyacrylarnide electrophoresis to purify 
lipoarnidase. Clean banding patterns were reproducibly obtained without any special 
techniques other than omitting SDS, 2-mercaptoethanol and boiling the sample. Both pre-
DEAE and post-DEAE fractions were used and activity was assayed using the LA-pABA 
hydrolysis and PDH inactivation assays. Some gels had multiple peaks of activity with 
both assays in gel slices but the two assays often were not in agreement. 
One attempt at native PAGE (NP5) involved loading pooled active DEAE fractions. 
No protein bands were found in the first five slices by silver staining. Slices #6, #7, #8, 
#9, and #11/12 (took the bottom of #11 and the top of #12 based on the stained lane) were 
electroeluted and assayed for PDH inactivation and reactivation activity. The results are 
shown in Fig. III-7. 
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Figure III-7. Lipoamidase Activity Assay of NPS Native PAGE Gel Slice 
Eluants by PDH Inactivation/Reactivation. Micromoles acetylphosphate is a 
measure of PDH activity. The activating system control activated > 3 µmole of PDH 
activity. The "inactivated set was simply apo-PDH and "reactivated" set was apo-PDH plus 
activating system. PDH indicates a control with no lipoamidase fraction added in stage one 
(activating system was added in stage two). DEAE indicates pooled active fractions from 
DEAE anion exchange chromatography which were loaded on the native gel. #6 - # 11, 12 
indicate slices from the native gel. Inactivated sets are those which had holoPDH incubated 
with the indicated treatment in the first stage of the assay and buffer added in the second 
stage. Reactivated aliquots are those which had holoPDH incubated with the indicated 
treatment in the first stage of the assay and lipoic acid activating system added in the second 
stage. 
Note that the DEAE treatment and all gel slices showed reduced PDH activity from the 
control level and incubation with activating system resulted in a loss of activity with the 
PDH control and further loss of PDH activity in all treatments except slice #6 and #9. Also 
note that activating system control was positive where treatment of apoPDH with lipoic acid 
and activating system resulted in more than 3.0 micromoles of acetylphosphate generated 
above a baseline of 0. Slice #9 showed a very slight recovery of PDH activity which does 
not seem significant but since activating system further reduced PDH activity in PDH 
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positive control, slice #7, #8, and #11/12 it may be significant. Slice #9 is also probably 
the same as slice #10 from a previous gel (data not shown). Slice #9 was analyzed by 
SDS-PAGE and contains only one band of -36 kDa. This corresponds to the major band 
in the best DEAE preparation. The protein in the slice #9 eluant was TCA precipitated and 
the pellet washed in preparation for sequencing. The prepared protein was submitted to the 
Peptide and Protein Sequencing Facility of the Core Facility at Oklahoma State University. 
No sequence data were obtained. 
Another attempt at obtaining activity from native gel slices (NP6) was made with a 
DEAE active fraction using only the LA-pABA cleavage assay. Only slices 10-12 showed 
any protein and these were assayed. Slice #10 generated 3.33 nmoles of pABA while 
slices #11 and #12 generated 0.54 and 0.21 nmoles respectively. Extracts from slice #10 
and #11 were analyzed by SDS-PAGE and both gave a major band at -35 kDa comprising 
>90 of the silver stained protein. 
Several attempts were made to use a homemade continuous elution electrophoresis 
apparatus and a Bio-Rad Prep Cell under native conditions with no success. 
Fractions from an HTP column with LipDom inactivation activity were loaded on a 
native gel, sliced and assayed for LipDom inactivation activity. Activity data was not 
obtained due to technical difficulties but SDS PAGE profiles of the slices were obtained. 
D. Hydroxy/apatite Column Chromatography and Subsequent N-terminal Sequencing 
Hydroxylapatite chromatography was used in an attempt to purify lipoamidase after 
DEAE anion exchange chromatography. With the first two columns (HTPl and HTP2), 
fractions were assayed by the PDH inactivation assay only. All other runs used the LA-
pABA assay to screen fractions and then the LipDom inactivation assay to establish 
lipoamidase activity. 
In the first column run (HTP 1) pooled active DEAE fraction was loaded on the 
column in 10 mM sodium phosphate. The A280 trace showed only a rise above baseline in 
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the flow through eluant and a slight rise off of baseline at -300 mM sodium phosphate 
(data not shown). Fractions from those regions were assayed with the PDH inactivation 
assay. Fig. III-8 shows that the 400 rru\1 elution buffer only control reduced PDH activity 
from 1.78 µmoles acylphosphate to 1.44 µmoles and the lipoamidase preparation loaded on 
the column (DEAE) reduced it to 1.08 µmoles. No decrease in PDH activity was seen with 
fractions from the l O rru\1 sodium phosphate flow through but fraction 24 and 25 ( -250-
300 mM sodium phosphate) reduced PDH activity from 1.78 µmoles acylphosphate to 0.86 
and 0.85 µmoles respectively. 
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Figure 111-8. PDH Activity Inactivation with HTPl Fractions. "PDH" is the 
no lipoamidase control, "DEAE" is a control of the preparation which was loaded on the 
HTP column. "Buffer" was the 400 rru\1 elution buffer only control. Fraction 9 and 10 are 
from the 10 mM NaPO; eluate and fraction 22, 23. 24 and 25 were from eluate at - 250-
300 mM sodium phosphate. 
The column was loaded with another aliquot of DEAE purified lipoamidase and run 
again (HTP2) with the sensitivity of the detector increased (Fig. III-9). This run produced 
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wide peaks roughly corresponding to the small peaks seen in the first run (HTPl) with 
large peaks in the 10 mM sodium phosphate and at - 170 mM sodium phosphate with a 
shoulder at -200 mM. Selected fractions were analyzed by the PDH inactivation assay. 
There is a general trend of increasing PDH inactivation with increasing sodium phosphate 
concentration. The exception is with fractions 26-28 where there is a peak of PDH 
inactivation which does not follow the buffer gradient. 
Fractions 23-25 of HTPl, which inactivated PDH, were pooled. Fractions 24-26 
and fraction 27-29 of HTP2 were pooled based on elution A280 pattern and PDH 
inactivation. The protein concentration of the pooled active fractions was determined and 
specific activity calculated (Table III-3). Aliquots of each pooled fraction containing 7.2 µg 
of protein were concentrated to approximately 10 µl by ultrafiltration. These samples were 
then subjected to SOS-PAGE and transferred to PVDF as described under "Preparation for 
N-terminal Microsequencing" in Chapter II (Methods and Materials). The resulting 
Coomassie Blue stained PVDF membrane had what appeared to be three identical bands in 
each of the sample lanes with differences in relative concentration (Fig. III-10, Table III-3). 
Calculation of molecular weight using Sigma Mark VII standards indicated band I 
to be -38,000 Da, band II to be -35,000 Da and band III to be -32,000 Da. The bands 
from the HTP2 fraction 27-29 (lane 4) were cut out and sequenced. Band I yielded a 
sequence of nine amino acids (Fig. III-11). Band II gave a 30 amino acid 
sequence(Fig.III-11) and band III yielded 16 amino acids which were of questionable 
accuracy due to sequencing instrument error. Later band III from HTP2 fractions 24-26 
was analyzed and fifty-eight amino acids of sequence (Fig. III-11) were determined. 
Analysis of these fifty-eight amino acids revealed that the initial band III sequencing attempt 
from HTP2 27-29 best guess matched the first sixteen amino acids. This confirmed that 
the bottom band in the three HTP preparations is the same and strengthens the case that all 
three bands in all three lanes are the same. 
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Figure 111-9. HTP Chromatography (HTP2) with PDH Inactivation 
Activity. Hatched bars indicate PDH inactivation. The bar labelled 380 mM sodium 
phosphate is the elution buffer control. The dashed line indicates the sodium phosphate 
elution gradient. 
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Figure 111-10. SDS-PAGE of Hydroxylapatite Fractions. This is a Coomassie 
Blue stained PVDF blot. Each Jane was loaded with 12 µg of protein. Bands labeled I, II, 
and III from lane 4 were cut from this blot and sequenced. Lane 1 and 5 are Sigma 
molecular weight markers. Lane 2 is HTPl pooled fraction 23-25 which has lipoamidase 
activity, lane 3 is HTP2 pooled fraction 24-26 which has low lipoamidase activity and lane 
4 is HTP2 pooled fraction 27-29 which has lipoamidase activity. Bands corresponding to 
band I in lane 4 were also present in lanes 2 and 3 but they are not evident in this picture. 
Table 111-3. Relative Amounts of Protein in Bands from Pooled HTP 
Fractions and Fraction Activity. Molecular weight is reported in Dal tons and was 
calculated based on Sigma Mark VII standard migration. Stain % is based on band density 
in each lane. The µ g values are from 7.2 µg of protien loaded and calculated from Stain%. 
Activity is PDH inactivation in µmole/min-mg for the pooled frac tion. 
HTPl 23-25 HTP2 24-26 HTP2 27-29 Molecular Weight 
Stain% I µg Stain% I µg Stain% I µg 
Band I 15% I 1.1 10% I 0.72 30% I 2.1 - 38,000 
Band II 25% I 1.8 30% I 2.16 20% I 1.4 - 35,000 
Band III 60% I 4.3 60% I 4.32 50% I 3.6 -32,000 
Activity 9 .5 6 .6 25.8 
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Band! 
ADVTAKMVK 
Band II 
MKIAIAGAGA MGSRFGLMLK QGRNDVLLII 
Band/II 
KKNDRIAAEG LANVATVNGV AAIVEVNSET DFVSKNEMFQ 
DLVKDIATKV AKNDPATM 
Figure 111-11. Amino Acid Sequence of HTP Pooled Fraction Proteins. 
Band I is the -39 kDa band, Band II is the -35 kDa band, Band III is the -31 kDa band. 
At a later date a -36 kDa band from a fraction with LipDom inactivation activity 
from a MonoQ Anion Exchange column yielded the 28 amino acid sequence shown below. 
-36 kDa band from MonoQ 
ADVTAKMVKE LRDMTGVGMM DAKKCLVK 
The first 9 amino acids are the same as band I from the HTP column fraction. A 
search of all 28 amino acids against the GenBank CDS database using a BLAST +BEAUTY 
server at the Human Genome Center, Baylor College of Medicine identified HTP band I as 
the first 28 amino acids of elongation factor Ts (EF-Ts). Compared to EF-Ts from 
Streptococcus pnuemoneae there is 62% identity with 88% similarity across the 28 
residues. Searches against other data bases with different search tools also gave the best 
matches with EF-Ts sequences. 
A BLAST +BEAUTY driven search of the GenBank CDS data base through the 
National Center for Biotechnology Information Blast server gave the best match between all 
58 amino acids of band III and amino acid 51-108 of EF-Ts from Spiroplasma citrii with 
50% identity and 67% similarity across the 58 residues. Based on the results of the 
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sequence database searches with the band I and band ill sequences, the two were combined 
assuming band I is the N-terminus and band III is amino acid 51-108. The resulting 
chimera was aligned with prokaryotic EF-Ts sequences as shown in Fig. ill-12. 
ECOLI 1 maEITASLVRELRERTGAGMMDCKKALTEangdielaienmrksgaik-
HAEIN 1 maEITASLVRELRDRTGAGMMECRKALVEangdielaidnmrksgqak-
STRPN 1 x-EITAKLVRELREKSGAGVMDAKKALVE 28-----------------
SPICI 1 m-EVTAQLVRELRDRTGAGMLDCKKALEDslagilkkqlhgyvqkgitk 
Ef ae a -DVTAKMVKELRDMTGVGMMDAKKCLVK 2 g,~r·,r,r•,r,-~~--,-r"~~r-..~r 
ECOLI aaXKA.GNVAADGVIKTKIDGNYGIILEVNCQTDFVAKDAGFQAFADKVL 
HAE IN aaXKA.GRVAAEGVILARVENGFGVLVEMNCETDFVAKDAGFLGLANEVT 
STRPN ----------------------------------------------------
SPICI aaKKSDRVAAEGLVGLVTKGDKQIIFEVNSETDFVAKNKQFKDLMATVG 
Efae xxKKNDRIAAEGLANVATVNGVAAIVEVNSETDFVSKNEMFQDLVKDIA 
ECOLI DAAVAGKITDV 108 
HAEIN DFAAANKG'TTI 108 
STRPN -----------
SPICI ETLI:NNDPKTV 108 
Efae TKVAKNDPA'lM 
Figure 111-12. Alignment of Sequenced Bands with EF-Ts. ECOLI is partial 
sequence of EF-Ts from E. coli sp# P02997, HAEIN is partial sequence of EF-Ts from 
Haemophilus influenzea sp# P43894, STRPN is all of the known sequence of EF-Ts from 
Streptococcus pnuemonea sp# P80715, SPICI is EF-Ts from Spiroplasma citrii sp# 
P 19216. Amino acids in bold are those which are either identical or similar in all 5 
sequences. 
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Band I and band III contain two EF-Ts signature sequences which are found in the 
N-terminal region of EF-Ts proteins. Fig. III-13 shows the standard notation with relevant 
band I and band III sequences and Fig. III-14 shows the signature sequences aligned 
against the combined band I and band III. The EF-Ts signature sequences do not represent 
any known functional motiffs but are sequences conserved in all known EF-Ts proteins 
and are not found in other proteins. 
PSOJ 126 L-R-x(2)-T-[GDQ]-x-[GS]-[LIVMF]-x(O,l)-[DENKAC]-x-K-[KRNEQ]-A-L 
Band I) L-R-D-M-T--G------V- -G---------M-----M------D------------A-K--K-----------C-L 
PSOJ 12 7 E-[LIVM]-N-[SCV]-[QE]-T-D-F-V-[SA]-K-R-N 
Band III) E-----V-----N--S----------E--T-D-F-V --S----K-R-N 
Figure III-13. EF-Ts Signature Sequences with Sequence from Band I and 
Band III. PS01126 is the EF-Ts signature sequence and Band I and III represent the 
band I and band III sequences from hydroxylapatite chromatography. Amino acids in [] 
represent variations at the given position, numbers in () represent the number of amino 
acids allowed, x indicates any amino acid is allowed. EF-Ts signature sequences and 
notation are from PROSITE: PD0C00867 at http://expasy.hcuge.ch/cgi-bin/get-prodoc-
entry?PDOC00867. 
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Figure 111-14. Alignment of Band I and Band III with EF-Ts Signature 
Sequences. Amino acids in bold letters represent the band I and band III sequence. 
Dashes in the sequence set off the signature sequence from the rest of the sequence. 
Numbers indicate the first and last amino acid in the band I and band III sequences which 
match the signature. Plain type letters represent the signature sequences while letters in a 
vertical line indicate acceptable variations at the given position. 
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A BLAST+BEAUTY [BLAST (65)] search with the 30 amino acids of band II did 
not provide a positive identity. The best match was with an internal segment (amino acids 
177-203) of a lipoamide dehydrogenase from Mycobacterium leprea with 48% identity and 
62% similarity across the 30 residues. A Blitz search through the European Molecular 
Biology Laboratory server (Blitz@EBI.AC.UK) gave the best match against the first 29 
amino acids of the UDP-Glucose 6-Dehydrogenase from Streptococcus pyogenes with 12 
matches (40% identity), 7 mismatches, 9 partial matches (70% similarity) and one gap 
across the 30 residues. A BEAUTY ( 66) search through the Human Genome Center, 
Baylor College of Medicine with xnu & seq filters gave the best match between amino acid 
12-27 of band II and amino acid 46-61 of endo-1,3-beta-glucosidase from Hordeum 
vulgare with 62% identity and 68% similarity across the 15 residues. A BEAUTY search 
with no filters gave the best match between amino acid 2-19 of band II and amino acids 7-
24 of lactate dehydrogenase from Bacillus subtilis with 44% identity and 69% similarity 
across the 18 residues. Alignment of the Band II sequences with these proteins is seen in 
Fig. III-15. 
UDP-glucose dehydrogenase is characterized by conserved motifs (67). One of 
these motifs is in the N-terminus and fits all eleven rules which define a NAD+-binding 
fingerprint as defined by Wierenga (68). The NAD+-binding fingerprint is defined by 11 
residues spread across 30-32 amino acids which specify a "~a~ fold" that binds the 
adenosine moiety of N AD+. Comparison of the band II sequence against the eleven rules is 
shown in Fig. III-16. HTP band II comforms to all ten of the rules which occur in the 
span of sequence that we have. Therefore, I conclude that HTP band II is a protein that 
contains a NAD+ -binding region. 
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UDP-GWC DEHY 1 MKIA'ilAGSGYVGI.SI.GVLLS-QNEVI'IVD 29 
rend II 
GUJCOSIDASE 
rend II 
rend II 
LAC DEHY 
rend II 
MKIA+AG+G +G G++L +N+V ++ 
·1 MKIAIAGAGAM3SRFGJ:.MLKCGR'NII 30 
--------46 GSGIGLII...J:NG3NDJ 61--
GS GL+L G NDVL 
1 MKIAIAGAGAM3SRFGJ:.MLKCGR'NII 30 
18~II30 
++ Q3 D L++I 
---7 KVALIGAG!NGSSYAFALIN(J}I'IDELVVI 36-----
K+A+ GAG +GS + L 
2 KIAIAGA.rnM3SRFGI.MLKCGRN0,JLLII 3 0 
LIP DEHY ----177 IVIVGAGAIGIEFGYVLKNYGVDVrN 203-----
I I GAGA+G FG +LK DJ++ 
rend II 
Figure 111-15. Alignment of Band II Amino Acid Sequence. UDP-GLUC 
DEHY is UDP-Glucose Dehydrogenase from Streptococcus pyogenes (A46089). 
GLUCOSIDASE is endo-1,3-beta glucosidase from Hordeum vulgare (P34742). LAC 
DERY is lactate dehydrogenase from Bacillus subtillis (Pl3714). LIP DERY is lipoamide 
dehydrogenase from Mycobacterium leprea (699253). Two alignments are indicated with 
LAC DERY. Letters between the two sequences designate identity, + designates similarity 
and blanks designate mismatch. 
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Figure 111-16. Analysis of HTP Band II Against Wierengas Rules for NAD+ 
Binding Amino Acid Fingerprints. The horizontal sequence is the sequence of HTP 
band II and the vertical list of amino acids are the amino acids which must occur at the 
designated position in order to define an NAD+-binding motif. The amino acids following 
the I in the rules are observed exceptions. 
Published Li:poamidase Sequences 
The only lipoamidase sequence in the databases, (accession # gi 299494) is 
from human breast milk (EC 3.1.1.13). The 33 amino acids shown below were 
determined from an endoproteinase Lys-C generated fragment (46). Analysis showed the 
enzyme to actually be pancreatic cholesterol esterase. 
Human breast milk lipoamidase (pancreatic cholesterol esterase) 
(KIPFAAPTKA LENPQPHPGW QTLK)(KLVSEF TIT) 
Interestingly, the part of the 33 amino acids beginning KIP and ending TLK [offset 
by ()] aligns with amino acid 53-78 of the cholesterol esterase, but does not contain two G 
residues, and the part beginning KL V aligns with amino acid 369-377. Band I, II and III 
do not align with the 745 amino acid protein. 
A search of The Institute for Genomic Research (TIGR) database with the band I, II 
and III sequences revealed that the genes from E. faecalis which code for these proteins 
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have in part been sequenced. All of the band II sequence is found in the translation of the 
gene gef_6215. Part of band III is found in the TIGR gene gef_6365. The band I 
sequence is not found. 
To separate further the 3 bands obtained from HTPl and HTP2 more HTP columns 
were run using the LA-pABA assay to probe protein peaks. HTP3 (Fig. III-17) gave a 
chromatogram that was similar to HTP2. The flow-through peaks were less pronounced 
than with HTP2 and there were more small peaks early in the elution. The peak at 
approximately fraction 23 looks like the HTP2 fraction 18 peak but it is at -220 rnM 
sodium phosphate and has a larger trailing shoulder. The bump at approximately fraction 
35 is at about the same sodium phosphate concentration as in HTP2. The activity profile 
from HTP3 shows the major LA-pABA cleaving activity in the -220 mM sodium 
phosphate peak with some at -100 mM and even less at -400 mM sodium phosphate. No 
SDS-PAGE analysis was done from HTP3 as the A280 pattern and activity profile did not 
indicate much difference from HTP2 
In HTP3 there was an obvious trailing shoulder on the major protein and LA-pABA 
peak. To separate this further, HTP4 (Fig. III-18) was run with an altered gradient 
profile. The gradient was increased from 10 to 150 mM sodium phosphate in 5 min, then to 
325 mM over 30 min, and finally increased to 500 mM over 10 min instead of the 25 min 
10 to 500 mM sodium phosphate gradient used previously. At first glance the 
chromatogram looks similar to HTP3 except that the broad flow-through and early elution 
peaks are combined and are more pronounced and the bump at -400 mM is flattened. The 
altered gradient did not result in a clean separation of the -220 mM peak from the trailing 
shoulder but it did separate two peaks of LA-pABA hydrolysis activity. The LA-pABA 
peaks are separated by one fraction. LipDom inactivation assays were performed on 
fractions 33 and 40 to verify lipoamidase activity in the LA-pABA active fractions. Fig. 
III-19 shows this data. 
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Figure 111-17. HTP3 Hydroxylapatite Chromatography. Hatched bars indicate 
LA-pABA hydrolysis activity. Dashed line indicates sodium phosphate elution gradient. 
Only the fractions indicated were assayed. 
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Figure 111-18. HTP4 Hydroxylapatite Chromatography. Hatched bars indicate 
LA-pABA activity. Dashed line indicates sodium phosphate elution gradient. Only the 
fractions indicated were assayed. Fraction #33 and #40 were assayed for LipDom 
inactivation (Fig. III-19). 
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Figure III-19. LipDom Inactivation Activity in HTP4 Fractions. LD is lipoyl 
domain only +control. DE is the DEAE enzyme preparation which was loaded onto the 
column, #33 and #40 are HTP fraction 33 and 40 respectively. Incubation time was 5 h at 
37 °C. Fraction #33 LipDom inactivation is significant at P=.05 with a t-stat of 6.32, 
Fraction #40 is not significant with at-stat of 1.87. T-Critical at P= .05 is 2.9. 
Due to the 4.7 nmole/min-mg decrease in lipoy l domain activity with the LD control 
and since the LD set, DE set and #33 set all had nearly identical T=O activities, and the LD 
and #40 set had nearly identical T=S activities, the T=S activities were analyzed by a two 
sample z-Test to determine if the average difference between the treatments was significant. 
DE, #33 and #40 were all compared to LD control at p=.05 . The DEAE purified 
preparation reduced the LipDom activity a statistically significant 4.2 nmole/min•mg, 
fraction 33 reduced the lipoyl domain specific activity by a statistically significant 2. 7 
nmole/min•mg and fraction #40 had no effect. Again I found that not all fractions 
exhibiting LA-pABA cleaving activity remove lipoic acid from the lipoyl domain. Fraction 
#33 was eluted at - 200 mM sodium phosphate; fraction #40 was eluted at -250 mM. 
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Based on the HTP4 results another HTP column (HTP5) was loaded and run under 
the same conditions as HTP4 and an identical chromatogram was obtained. The fraction 
which corresponded to fraction 33 from HTP4 was concentrated and the buffer changed to 
20 mM potassium phosphate pH 7 in a spin ultrafiltration device. It was then 
electrophoresed on an 8% native polyacrylamide gel. Protein bands were sliced and 
assayed for LipDom inactivation. A portion of each band was saved and SDS-PAGE 
profiles were obtained (Fig. III-28). No LipDom inactivation was observed in the crushed 
gel pieces. However a native PAGE profile of the HTP fraction and SDS-PAGE profiles 
of the Native slices were obtained but did not give any further insight into lipoamidase 
identity. 
E. Size Exclusion Chromatography 
Size exclusion chromatography was performed on a TSK 3000 SW column with 
AS3DP fraction to determine what resolution could be obtained and whether lipoamidase 
activity could be detected in the fractions. All fractions assayed across the elution peak 
produced a significant loss of PDH activity; thus there was not sufficient resolution of 
proteins in the range of interest to make the approach profitable. 
F. Hydrophobic Interaction Chromatography 
HIC was tried in an attempt to utilize potential protein hydrophobicity for 
separation. There are two ways in which lipoamidase might react with a hydrophobic 
column. The first is the obvious and most common, the interaction between hydrophobic 
areas on the surface of the protein and the column. The second would utilize the natural 
substrate requirement of lipoamidase for the eight carbon lipoic acid where lipoamidase 
might bind the column in the active site. 
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A butyl and an octyl column were tried under different loading and elution 
conditions but no lipoamidase activity and very little protein was retained on the columns. 
The method was abandoned. 
G. CM Cation Exchange Chromatography 
An Econo CM column from .Bio-Rad was used with the dialyzed pellet from the 
third ammonium sulfate cut (AS3DP). No lipoamidase activity was retained on the column 
so the method was abandoned. 
H. MonoQ Anion Exchange Chromatography 
Since anion exchange chromatography purified lipoamidase, a resin other than 
DEAE was examined. Initial experiments were done with a Bio-Rad Econo Q (quaternary 
amine) column run in Bis-Tris buffer and eluted with a linear gradient of 0.0-1.0 M NaCl 
in Bis-Tris, pH 7.0. This column yielded a small amount of protein washed through and a 
peak in the eluant. Analysis of some of the fractions with the PDH inactivation assay 
showed a peak of activity in the washed through protein and in the NaCl eluant but it is 
difficult to separate the activity in the eluant from the effect of NaCl on PDH. An analysis 
of the fractions with the LA-pABA assay also found activity in the washed through protein 
and in the NaCl eluant. Verification of lipoamidase activity by inactivation and reactivation 
of PDH was unsuccessful. SDS-PAGE showed that none of the active fractions were 
homogeneous. Based on these results a MonoQ FPLC column was tested in order to get 
better resolution and more activity. 
A MonoQ HR5/5 column loaded with pooled active fractions from the 0.15 M KCl 
DEAE peak gave little protein in the flow through while the eluant gave an interesting 
pattern from about 0.125 M NaCl to approximately 0.375 M NaCl with at least 10 peaks all 
run together (Fig III-20). Initial assay of the fractions with the LA-pABA assay found 
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strong activity (Fig. III-21) in the flow through fraction (160 mmole/min/mg) and much 
weaker activity in the eluant (2.4 nmole/min/mg). A check of the most active LA-pABA 
fractions with the LipDom inactivation assay showed no activity in flow through fraction 8 
but strong LipDom inactivation in the eluant fraction 52 (p=.05) (Fig. III-22). SDS-PAGE 
was performed on a group of fractions around fraction 52. A - 36 kDa band which seemed 
to correlate in intensity with peak LA-pABA cleavage activity was selected and N-terrninal 
sequence determined. A sequence for 28 amino acids was obtained and the first 9 amino 
acids were the same as band I obtained from HTP chromatography (Fig. III-:-11). 
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Figure 111-20. Ql MonoQ Chromatography with 0.15 M KCI DEAE 
Purified Lipoamidase Loaded. Hatched bars indicate LA-pABA hydrolysis activity. 
Dashed line indicates KCl elution gradient. Fraction 8 and 52 were assayed for LipDom 
inactivation. Fraction 8 reduced LipDom activity a statistically non-significant 2.5 
nmole/min•mg (t-stat = 2.4), fraction 52 reduced LipDom activity a statistically significant 
17.5 nmole/min•mg (t-stat = 23.8, t-Critical for P=.05 is 2.9). 
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Figure 111-21. LA-pABA Activity in MonoQ Fractions. Circles are the flow 
through fractions. Boxes are KCl eluant fractions. Note the difference in scale, the peak 
activity in the flow through is 160 and KC! eluant is 2.38 nmole/min/mg. 
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Figure III-22. LipDom Inactivation Activity in MonoQ Fractions. Outlined 
bars are T=O values and solid bars are values after 4 h incubation with the indicated 
fraction. LD is the lipoyl domain only positive control, BisTris is the MonoQ running 
buffer negative control , Q #8 is fraction number 8 from the MonoQ column (t-stat = 2.4) 
and Q #52 is fraction 52 from the MonoQ column (t-stat = 23.8, P =.05 t-Critical is 2.9). 
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Three other MonoQ columns were run with the 0.15 M DEAE fractions loaded and 
reproducible chromatograms and activity profiles were obtained. One DEAE column run 
yielded LipDom inactivation activity in both the 0.1 M KCI (lipoamidase activity of 408 
nmole/min/mg in the peak fraction) and 0.15 M KCI elution (lipoamidase activity of 117 
nmole/min/mg in the peak fraction). The active fractions from these peaks were pooled 
separately and run on the MonoQ column with the result of nearly identical chromatograms 
and activity profiles (Fig. ill-23). Even when HTP active fractions were loaded the profiles 
were nearly identical to DEAE loaded MonoQ runs and purification was only slightly better 
(Table III-4). 
Table 111-4. Purification of Lipoamidase On MonoQ Based on the LA-
pABA Assay. Activity data is based on the generation and detection of pABA from LA-
pABA cleavage. 
Fract10n Specitlc Activity Total Activity Yield% Purification 
(nmole/min·mg) (nmole/min) 
0.15MDEAE 0.95 2.36 
Q#52 2.33 0.09 3.8 2.5 
0.15 MDEAE 0.95 2.36 
HTP 3.25 0.10 4.2 3.4 
Q#50 5.30 0.03 1.0 5.6 
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Figure 111-23. MonoQ Anion Exchange Chromatography. This figure shows 
0.1 M KCI DEAE purified lipoarnidase. The 0.15 M KCI DEAE purified fractions from the 
same column had nearly identical activity but the activity of the flow-through peak is 
reduced. Hatched boxes indicate LA-pABA hydrolysis activity and dashed line indicates 
NaCl elution gradient. 
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I. Attempt to Purify Lipoamidase from E. coli 
An attempt was made to purify lipoamidase from E. coli (Crookes Strain) using 
the same procedure as for E. f aecalis. The protamine sulfate step worked very well for 
removal of PDH from the extract but no lipoamidase activity could be detected. Koike and 
Suzuki (69) also reported no lipoamidase activity in this strain. Thus I verified their 
observations. 
J. Summary of Additional Purification 
Table III-5 lists purification data for HTP and MonoQ fractions starting from DEAE 
active fractions. DEAE active fractions were the final step in the Reed, Suzuki protocol (8) 
where the PDH inactivation assay was used. The HTP fractions assayed with the PDH 
inactivation assay (Table III-5) can be compared to their results and constitute further 
purification of the enzyme lipoamidase. Table III-2 shows that starting material (pH 6 
SONS) has a specific activity of 9.6 nmole/min-mg and 1136 nmole/min total activity (data 
not shown in table III-2). From this beginning material HTP fraction II27-29 shows 801 
fold purification with 5.4% yield. However the activity in HTP II27-29 was not verifiable 
by the PDH inactivation I reactivation assay. 
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Table III-5. Summary of Additional Lipoamidase Purification Beyond 
DEAE. * values reported are decrease in nmole acetylphosphate generated/min-mg; 
"values reported are nmole TNB lost /min-mg; ' values reported nmole pABA 
generated/min-mg. Notes; 1- these are the fractions sequenced. ; 2- From an HTP column 
run under slightly different conditions from that which produced 124-26 etc. ; 3- this 
fraction was also assayed by LipDom Inactivation. ; 4- this fraction was also assayed by 
LA-pABA cleavage. 
Method Fraction Starting Assay Specific Purifica- Recovery Notes 
Material Used Activitv tion 
HTP 0.15 M PDH *553.8 
DEAE Inactivate 
123-25 *2210 4.0 7.8% 1 
II24-26 *2100 3.8 2.1% 1 
II27-29 *7714 13.9 5.4% 1 
HTP 0.15 M Lip Dom "97.1 
DEAE Inactivate 
HTP #33 "141 1.46 60% 2 
MonoQ 0.15 M LA-pABA '0.95 
DEAE 
Q#52 '2.33 2.5 3.8% 3 
MonoQ 0.1 M LA-pABA '5.68 
DEAE 
Q#42 '347 61 3.7% 
MonoQ 0.15 M Lip Dom "117 
DEAE Inactivate 
Q#52 "721 6.2 76% 4 
K. Protein Profiles from Verified Lipoamidase Fractions 
Five fractions verified to have lipoamidase activity by either a recoverable PDH 
inactivation or by LipDom inactivation were analyzed by SDS-PAGE and silver staining. 
Comparison of the silver stained SDS-P AGE profiles of these fractions shows many 
protein bands ranging from -27 kDa to -65 kDa (Fig. III-24). All five fractions have a 
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band at 30-31 kDa, one at 33-34 kDa, one at 35-36 kDa and one at 38-40 kDa. Table ill-6 
shows the occurence of these bands and their relative quantity. 
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Figure 111-24. SDS-PAGE Banding Profile of Fractions with Either PDH 
Inactivation/Reactivation or LipDom Inactivation Activity. S= molecular weight 
standards. 113= DEAE 0.1 M KCl fraction . 184=DEAE 0.15 M KCl fraction. H34= 
hydroxylapatite fraction. The .1 Q= monoQ fraction from 0.1 M KCl DEAE load. l 5Q= 
monoQ fraction from 0.15 M KC! DEAE load. All lanes are silver stained images. All S 
lanes are from the same gel as the fraction they are paired with. 
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Table 111-6. Composition of Total Stained Protein Bands in the 30-40 kDA 
Range from Lipoamidase Fractions. Band percentages were determined by 
densitometry using an Alpha Innotech Chemlmager 4000. Values reported are the % of 
band density the particular band contibutes to band density of all bands in the lane (for 
example the 31 kDa band from the CHT sample comprises 14% of total protein stained in 
the CHT sample). 
Band MW % of CHT % of 0.15 % of 0.1 % of 0.1 % of 0.15 
(kDa) bands DE>Q DE>Q DE bands DE bands 
bands bands 
30 07 17 02 
31 14 07 10 05 22 
32 07 
33 20 08 15 16 
34 08 06 
35 21 09 02 21 
36 08 
37 06 
38 03 11 
39 04 03 02 
40 04 04 
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CHAPTER IV 
DISCUSSION 
A. General 
Lipoamidase first came to my attention when I began a project to examine lipoic 
acid addition to and removal from multi-enzyme complexes. There are four systems in 
which lipoic acid activation has been studied: animal, plant, yeast and bacteria. Research 
was underway in other laboratories on the animal system and E. coli. This left the yeast 
system to be examined further. To study lipoic acid activation a substrate, (a non-
lipoylated) a.-keto acid dehydrogenase, is required. One way to acquire this substrate is by 
treating holo dehydrogenase with lipoamidase. This is why I originally started out to 
purify lipoamidase, but it is clear that lipoamidase is a very useful tool. 
Lipoic acid is attached to the £-NH2 of lysine residues, and the disulfide to 
sulfhydryl redox reaction is essential for a-keto acid dehydrogenase function. Lipoic acid 
' ' 
is also involved in recognition of phosphorylation sites in a-keto acid dehydrogenases by 
regulatory kinases. Lipoic acid (lipoyl domains) also occur in proteins other than the a-
keto acid dehydrogenases. However the function of Iipoic acid in these other proteins is 
not clear. There are two ways to study lipoic acid involvement and mechanism: 
mutagenesis of the lipoic acid containing protein to remove the lipoylation site or specific 
removal of the lipoic acid from purified protein. The result of either approach is a protein 
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with either partial or complete deletion of lipoic acid. Observing the effect of delipoylation 
on activity/kinetics of the protein gives insight into the function of lipoyl domains. Of the 
two approaches the application of lipoamidase is the easiest and most straightforward. 
Lipoylation/delipoylation is also possibly a control system used to modulate activity 
of Iipoy1 containing enzymes similar to adenylation/deadenylation with glutamine 
synthetase, but involves a functional cofactor. Glutamine synthetase sensitivity to feedback 
inhibition is altered by the degree of adenylation on tyrosine residues; the higher the degree 
of adenylation the more susceptible the enzyme is to pr~duct inhibition (70). Recall from 
Chapter I that lipoic acid is involved in interactions with a regulatory kinase in eucaryotic a-
keto acid dehydrogenases ( 16). Also recall that in E. coli approximately half of the lipoyl 
domains can be removed with no apparent overall decrease in dehydrogenase activity ( 18). 
The degree of lipoylation may alter dehydrogenase responsiveness to product feedback 
inhibition or phosphorylation/dephosphorylation. Lipoamid_ase could be involved in 
regulating the degree of lipoylation and it would be useful in studying whether such 
regulatory mechanisms exist. 
Recently Dr. Thomas Roche at Kansas State University expressed an interest in 
lipoamidase as a tool for his studies on the role of lipoic acid in the 
phosphorylation/dephosphorylation of the a-keto acid dehydrogenases. Personal 
communication with him revealed that his lab had worked on purifying lipoamidase for a 
time but had abandoned that pursuit. Dr. Roche graciously provided recombinant human 
lipoyl domain and an assay (LipDom inactivation assay) for determining the lipoic acid 
content of those domains to be used as an assay for lipoamidase activity. 
Many papers have been published concerning mammalian lipoamidase but no 
complete sequence information has been published. The only known sequence is a partial 
amino acid sequence from human breast milk (chapter III p. 76). There are some 
discrepancies involving enzymes assumed to be lipoamidase. In serum and breast milk, 
enzymes assumed to be lipoamidase are in fact biotinidase (43, 44) and a form of pancreatic 
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cholesterol esterase (46) respectively. Oizumi (47) found that the pig brain enzyme called 
lipoamidase is a multiple hydrolase since the only specificity requirement is that lipoic acid 
be the acyl group of the substrate. 
Much remains unknown about lipoamidase and it is not presently conveniently 
available as a research tool. To fill this need I set out to purify lipoamidase to 
homogeneity, determine a partial amino acid sequence (either N-terminal or internal), 
design oligonucleotide probes based on the protein sequence and then use the probes to 
clone and sequence the lipoamidase gene. Once the gene is cloned it can be used in an 
expression vector which will allow production and purification of large quantities of active . 
lipoamidase. 
B. Initial Experiments 
I began to isolate lipoamidase by following the purification procedure of Suzuki and 
Reed (31) since it (see Fig. 11-6) so effectively and easily separates the PDH, lipoamidase 
arid the activating system. 
Early experiments were encouraging, after the DEAE step there was only one major 
band (-36 kDa) and 3-5 minor bands (>35 kDa) present in the active fractions by 
Coomassie Blue staining of SDS-PAGE gels (Fig. IIl-1). I was able to inactivate 
holoPDH and then reactivate it by incubation with lipoic acid and an activating system 
preparation (Fig. 111-3). Table III-2 shows however that purification was 58 fold with 10 
% yield. Since the objective was to obtain homogeneous lipoamidase, I needed to eliminate 
the other proteins. 
C. Further Purification with Hydroxy/apatite Chromatography 
Initial experiments with hydroxylapatite (HTP) column chromatography gave 
encouraging results in that only 3 protein bands were seen in the active fractions. Fig. III-8 
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shows activity data for 6 fractions. Initially the DEAE preparation and HTP fractions 9-10, 
and 22-23 were assayed. When fraction 23 was found to have activity, fractions 24 and 25 
and the elution buffer were assayed. Notice that the elution buffer alone (Fig. III-8, 
"Buffer") inactivated PDH as much as fraction 23 but it was only half of what fractions 24 
and 25 had inactivated. As previously noted the only way to be certain that observed PDH 
inactivation is due to lipoamidase and not protease or high salt or other factors is to reattach 
lipoic acid to E2 and observe PDH reactivation. The inactivation/reactivation assay was 
attempted with these fractions but was not successful. Unfortunately all of my activating 
system preparations after early 1994 were unable to reactivate inactivated PDH and they 
also reduced the activity of control PDH even though they were capable of activating E. 
faecalis apoPDH. When reactivation failed, fraction 22, 23 and the elution buffer were 
reassayed with 3 times as much sample. Fraction 23 showed - 3 fold increase in PDH 
inactivation while fraction 22 and the elution buffer showed no increase. This indicated 
that the activity in fraction 23 was not simply due to a salt effect. SDS-PAGE was 
performed on the fractions from HTPl and fractions from the next run (HTP2). Fig ill-10 
shows three bands were present at -32 kDa, 35 kDa and 37 kDa in all three samples. 
Examining the relative signal intensity (Table III-3) of the three bands from the three pooled 
samples and the PDH inactivation specific activity of the pooled samples suggests that band 
I is lipoamidase. Specific activity is greatest in HTP2 27-29, lower in HTPl 23-25 and 
lowest in HTP2 24-26. Band I signal intensity is also greatest in HTP2 27-29 and lowest 
in HTP2 24-26. Band II signal intensity is greatest in HTP2 24-26 arid lowest in HTPl 
23-25 and band III is roughly equal in the three fractions. Since HTP2 27-29 has the 
greatest specific activity and there is relatively more band I in this fraction than the other 
two fractions band I may be lipoamidase. 
These three bands were sequenced and analyzed. The amino acid sequence 
similarity between band I and band III with EF-Ts and the.presence of an EF-Ts signature 
sequences in both band I and band III (Fig. III-13, III-14) indicate that these proteins are 
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EF-Ts. EF-Ts is part of the translation machinery in prokaryotes where it binds the EF-Tu 
GDP complex and induces the exchange of GDP for GTP which primes the elongation 
complex for the next round of amino acid addition. EF-Ts remains bound until GTP has 
been hydrolyzed. EF-Ts is also present in eucaryotic chloroplasts (72) and mitochondria 
(73) where its function is presumed to be similar. 
Band I contains the N-terminus of EF-Ts and may be the complete protein since its 
molecular weight is similar to other bacterial EF-Ts proteins. Band III corresponds to a 
fragment of EF-Ts beginning at amirio acid 51. Fig. III-12 shows the alignment of the 
band I and band III sequences together against 4 other bacterial EF-Ts sequences. 
Examination of the TIGR data base revealed that at least part of the genes for the band I, II 
and III proteins have· been sequenced. The E. faecaslis sequences found in the TIGR 
database are raw DNA sequencing data which are classified as "Enterococcus faecalis 
unfinished fragment of complete genome" and have not been published. The TIGR gene 
· gef_6365 contains the coding sequence for amino acid 7- 58 of band III with a one base 
pair deletion which creates a framshift in the putative protein. Band I is not found but the 
first 6 amino acids of band III is not found either. This suggests that the N-terminus of the 
EF-Ts gene has not been sequenced by TIGR. There is little doubt that the band I and band 
III proteins are EF-Ts. The sequence of E. faecalis EF-Ts has not been reported and I 
have determined 86 of the putative 109 amino acids. I will submit this to one of the 
databases by direct submission as a putative EF-Ts. 
The partial EF-Ts sequence from S. pneumoniae was determined by Kolberg et al. 
(78) by screening bacterial and mammalian cellular protein extracts with antibodies raised 
against pneumococcal cell extracts. One of the antibodies reacted with a -43 kDa protein. 
The N-terminal sequence of 28 amino acids identified this protein as EF-Ts. The antibody 
reacted with all streptococcal strains tested ( 12 total) but neither of the two enterococcal 
strains (including E. faecalis). The antibody did not react with any of the other bacterial 
strains or mammalian cells tested. The authors state that differences in reactivity with this 
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antibody between streptococcal and enterococcal strains support the taxonomic split of 
streptococci and enterococci into separate genera. If band I is the full length protein, E. 
faecalis EF-Ts has a molecular weight of 36-37 kDa. S. pneumoniae is -43 kDa; this is 
further support for. the new classification. Of the 5 proteins examined the S. pneumoniae 
is the largest at -43 kDa, the other 4 are all smaller with E. faecalis band I at 36-37 kDa, S. 
citrii at 32.8 kDa, E. coli at 30.2 kDa and H. influenzae at 30.0 kDa. 
Analysis of HTP band II shows it to be similar to the amino terminus of UDP-
glucose dehydrogenase from S. pyogenes (a Gram+ cocci) and other dehydrogenases (Fig. 
III-16). But 40% identity and 70% similarity across only 29 amino acids is not an absolute 
identification. Examination of the TIGR database showed that the gene encoding the band 
II has been partially sequenced and identified as gef_6215. The evidence that band II is a 
dehydrogenase is strengthened by the identification of a NAD+-binding fingerprint in the 
same location as the one present in the UDP-glucose dehydrogenase. 
Even with the identification of band I and band III as EF-Ts they cannot be 
eliminated as being lipoamidase. An SDS-PAGE protein band from a single MonoQ 
column fraction ,#52, which had LA-pABA hydrolysis and LipDom inactivation activity is 
EF-Ts. The fraction was not homogeneous by SDS-PAGE but the band was selected 
because it was a major band, it was present only in fractions 51-53 and it correlated with 
LA-pABA activity in the fractions. Note that all of the fractions in the peak were assayed 
with the LA-pABA assay and fraction 52 was assayed with the LipDom inactivation assay. 
Thirty amino acids of the sequence were obtained from the band, and the first nine were 
identical to the HTP band I (EF-Ts). This finding, along with the HTP results, places EF-
Ts in fractions which are active with all three assays. Finding EF-Ts in fractions with 
activity for all three assays is not proof that EF-Ts is lipoamidase, but the correlation 
between EF-Ts signal intensity and PDH inactivation specific activity in th.e sequenced 
fractions is further evidence that it is. 
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EF-Ts is not just a binding protein which regulates EF-Tu during protein 
biosynthesis. Highly purified EF-Ts preparations from E. coli also have guanylate cyclase 
activity (74). Also the EF-Tu.Ts complex is part of the RNA bacteriophage Q ~ RNA 
replicase (75). The EF-Tu•Ts complex is required for iniation of RNA synthesis (75) but 
EF-Ts does not dissociate from EF-Tu in the process as it does in its normal function (76). 
There are also examples of lipoamidase with multiple activities and other enzymes 
with lipoarnidase activity. Amino acid sequencing of LA-pABA cleaving lipoamidase in 
human milk identified it as bile salt-stimulated lipase. Mutagenic abolition of the esterase 
activity did not affect the LA-pABA activity ( 46). This is a lipoamidase enzyme with two 
independent activities. The enzyme in pig brain which cleaves lipoyl-lysine has been 
characterized as a multiple hydrolase ( 47, 48) which will cleave amide, ester, or peptide 
bonds. There is no data as to the independence of these activities but it is not a rigidly 
specific enzyme. 
There are many other proteins which have multiple activities. Adenylosuccinate 
lyase (ASL) catalyzes two reactions in the purine synthetic pathway, but in Bacillus subtilis 
it also has a role in regulating glutamyl-tRN A synthetase activity (71 ). These two activities 
by the same protein may be a control link between nucleotide and protein synthesis. 
Mammalian acetyl-CoA carboxylase, which is involved with fatty acid biosynthesis, 
catalyzes a CO2 activation reaction and a carboxylation. Both active sites and a biotin 
carboxyl carrier are contained in a single polypeptide (70). Mammalian fatty acid synthase 
is 500 kDa homodimer which catalyzes seven different reactions in fatty acid synthesis 
from acetyl-CoA and malonyl-CoA (70). 
Acetyl-CoA carboxylase and fatty acid synthase catalyze sequential reactions in a 
biosynthetic pathway, but one of the activities of B. subtilis ASL appears to be unrelated to 
the other activities. The regulation of glutamyl-tRNA synthetase is a binding function from 
a protein which also catalyzes the elimination of fumarate from adenylosuccinate. If EF-Ts 
is also lipoamidase it follows the same pattern; a single protein with both catalytic 
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(lipoamidase) and regulatory binding (EF-Ts) activity. Although the connection is not 
evident, it is possible that EF-Ts is also lipoamidase and may provide a regulatory link 
between carbohydrate metabolism (and thereby cellular metabolic condition) and 
translation. 
The physiological function of lipoamidase is unknown. Its capacity to remove 
lipoic acid from lipoyl containing proteins suggests two possible functions. One function 
might be in regulation of a-keto acid dehydrogenase complexes since removal of lipoic acid 
results in diminished or abolished complex activity. Recall that Stepp et al.(18) found that 
with the E. coli a-keto acid dehydrogenase about half of the lipoyl groups in the complex 
could be removed without significantly affecting complex activity. This makes the complex 
activity very stable but after removal of half of the lipoyl groups complex activity would be 
very sensitive to lipoamidase removal of lipoyl groups. The other function could be lipoic 
acid salvage and recycling. . Oizumi (38) found that human serum lipoamidase could 
remove lipoic acid from bovine PDH only after the PDH had been proteolyzed. Neither 
function would require a stand alone enzyme and a single protein with both EF-Ts and 
lipoamidase activity would not hamper either activity. 
Since lipoamidase was not pure and the correlation between EF-Ts and lipoamidase 
was not absolutely solid, more HTP columns were run. These were done using the LA-p-
ABA assay and altering the elution gradient. No further separation of the three bands was 
achieved, but lipoamidase activity was established by the LipDom inactivation assay in a 
fraction corresponding to the ones sequenced. This fraction has multiple bands by silver 
staining. Three of the twelve bands are the same molecular weight as the three bands 
sequenced (Fig III-28 lane H34, and Table III-5). The presence of proteins of about the 
same size as those sequenced in a fraction which inactivates LipDom is further reason not 
to dismiss EF-Ts as being responsible for lipoamidase activity. For the same reason 
neither can I dismiss band II even though it is not evident why an amide hydrolase would 
need an NAD+-binding domain. Also, finding LipDom inactivation activity in a fraction 
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corresponding to the ones from which the three sequences were obtained establishes the 
presence of lipoamidase in the sequenced fraction in the absence of PDH reactivation. 
D. Further Purification by MonoQ Ion Exchange Chromatography 
Since I was not able to purify lipoamidase to homogeneity with hydroxylapatite 
chromatography, I examined MonoQ ion exchange chromatography. The first column run 
(Fig. III-20) was loaded with active DEAE purified sample and had at least 10 A~80 peaks 
run together. Fractions were screened with the LA-pABA assay and two peaks of activity 
were identified, one very active (fraction 8 peak) which did not inactivate lipoyl domains 
and one very weak (fraction 52 peak) which inactivated lipoyl domain by half (30 
nmole/min-mg to 15 nmole/min-mg). Table III-4 shows that fraction 52 achieved only 2,? 
fold purification of LA-pABA activity with just 3.8% .yield from the previous step. Table 
III-5 shows 6.2 fold purification and 76% yield of LipDom inactivation activity from the 
previous step. This large difference in yield between the LA-pABA assay and the LipDom 
inactivation assay indicates how non-specific the LA-pABA assay is for lipoamidase. Yet it 
is still useful for screening large numbers of fractions. When fraction 52 was analyzed by 
SDS-PAGE 6 protein bands were found (Fig. III-28 .15Q lane and Table III-5). The most 
prominent band (-36 kDa), was only found in fractions 51-53 and was sequenced and 
identified as EF-Ts. As previously discussed this is the same protein which was sequenced 
in 2 bands from hydroxylapatite chromatography. 
With lipoamidase activity found in MonoQ fractions from 6 silver stained proteins I 
attempted to further separate the 10 peaks and 6 proteins by altering the elution gradient and 
the sample loaded on the column. Extending the gradient did begin to separate the A280 
peaks but it also diluted LA-pABA activity to undetectable levels. Changing the fraction 
loaded onto the MonoQ column to hydroxylapatite, or 0.1 M KCl DEAE purified sample 
did not result in homogeneous protein. Table III-4 shows purification data for MonoQ 
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fractions with DEAE purified protein loaded and with DEAE>HTP purified protein loaded. 
The purification with HTP sample is only 5.6 fold with only 1 % yield. 
E. Multiple Peaks of LA-pABA Activity 
The presence of multiple peaks of LA-pABA cleaving activity from column 
chromatography was a recurring event. It first occurred with DEAE fractions using the 
LA-pABA cleavage assay. Two peaks of activity were detected with the most active one 
unable to inactivate PDH. In later purifications, the sample which was applied to HTP and 
MonoQ columns was from the DEAE peak which inactivated PDH. Subsequently multiple 
LA-pABA activity peaks were also found with IvfonoQ fractions (DEAE>monoQ and 
DEAE>HTP>MonoQ). MonoQ fractions were assayed with the LipDom inactivation assay 
to establish lipoamidase activity. Again I found that the peak with greatest LA-pABA 
activity did not inactivate lipoyl domains. It may be that there are multiple enzymes, which 
can cleave LA-pABA in E. faecalis, which are being separated on these columns. The 
lipoamidase literature supports this possibility (see below). In fact in rat liver there are two 
pH optima for LA-pABA hydrolysis but only one optimum for lipoyl-lysine hydrolysis 
(42). Thermostability, pH stability, inhibition pattern, tissue abundance and subcellular 
localization data indicate that the enzyme responsible for lipoyl-lysine hydrolysis activity is 
different from LA-pABA hydrolysis but the same as biotinidase. It is also possible that 
partially degraded lipoamidase can hydrolyze the synthetic LA-pABA substrate but not the 
natural substrate. 
With mammalian lipoamidase investigations, enzymes having lipoamidase activity 
as defined by LA-pABA hydrolysis were subsequently found to be other enzymes or have 
loose specificities. Human serum LA-pABA and lipoyl-lysine hydrolyzing activities 
respond differently to inhibitors ( 41). These two activities are different enzymes and the 
one responsible for lipoyl-lysine cleavage is, in fact, biotinidase ( 42). Garganta et al. ( 43) 
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compared human serum biotinidase and lipoamidase characteristics and i~unoprecipitated 
both activities with an anti-:.biotinidase antibody. They concluded that the two activities 
were due to the same enzyme. Nilsson et al. (44) concluded that serum lipoamidase 
activity was biotinidase when a boy with severe biotinidase deficiency was also 
lipoamidase deficient. Serum lipoamidase and biotinidase activities copurified through six 
steps (45). In human breast milk the enzyme referred to as lipoamidase was purified, 
proteolytically cleaved and partially sequenced. It is a bile-salt stimulated lipase instead of 
lipoamidase (46). Oizumi (47, 48) found the enzym~ from porcine brain to require lipoic 
acid in its substrate but in an amide, ester, or peptide bond. There were only loose 
requirements for lipoic acid attachment, they referred to this. enzyme as a multiple 
hydrolase. These cases set a precedent for using synthetic substrates for the determination 
of lipoamidase activity but many of them provide evidence that synthetic substrates are not 
very specific. 
Table IV-1 lists enzymes which were originally identified as lipoamidase. Both the 
human bile salt stimulated esterase (pancreatic cholesterol esterase EC 3.1.1.3) and human 
biotinidase (EC 3 .5 .1.12) have been cloned and sequenced. There are no detectable 
identical regions between the two yet both have LA-pABA cleaving activity. The only two 
proteins originally designated lipoamidase which still are, are liver enzymes. The enzyme 
from rat liver though has two pH optimums, this indicates either 2 active sites in one 
enzyme or multiple enzymes. Chromatography data generated during this purification of E. 
faecalis lipoamidase suggests there are multiple LA-pABA cleaving enzymes in this system 
also. In all instances only one of the fractions could inactivate PDH or LipDom which 
indicates that one of the LA-pABA cleaving fractions is not really lipoamidase. 
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Table IV-1. Lipoamidase and Biotinidase Comparisons. Initial Designation is 
what the enzyme was first identified to be, Current Designation is what it is now called 
after further experiments. Liplys is lipoyl-lysine, ser hydrolase designates a serine type 
hydrolase. · 
Initial Designation 
Lipoamidase 
Lipoamidase 
Biotinidase 
Biotinidase 
Serum lipoamidase 
Liver biotinidase 
Liver lipoamidase 
Brain lipoamidase 
Breast milk 
lipoamidase 
Liver lipoamidase 
Liver lipoamidase 
Weight 
(kDa) 
60-70 
51 
61 
66-76 
76, 110 
70 
60 
140 
135 
Activity Measured 
LA-pABA, esterase 
LA-pABA, esterase 
B-pABA 
B-pABA 
B-pABA, Liplys, 
LA-pABA 
B-pABA 
LA-pABA 
Liplys 
LA-pABA, lipolytic 
Liplys, B-pABA 
LA-pABA 
Comments Current 
Designation 
Cholesterol 
esterase 
Rat clone, 2 Cholesterol 
active sites esterase 
Human Biotinidase 
clone 
Human Biotinidase 
Human, 20k Biotinidase 
fold 
enriched 
Guinea pig, Biotinidase 
thiol 
hydro lase 
Guinea pig, Lipoamidase 
ser hydrolase 
Pig, 600 fold Multiple 
enriched Hydro lase 
4.4k fold Cholesterol 
enriched, ser esterase 
hydro lase 
Rat 
Rat, 2 
optimal pH 
B iotinidase 
Lipoamidase 
All of the above instances are from mammalian sources and so I ask, what about 
prokaryotic lipoamidase? The only report of prokaryotic lipoamidase is the groundbreaking 
work of the Lester Reed group (29, 31) which is the basis for this attempt to purify 
lipoamidase from E. faecalis. Suzuki and Reed indicated that post DEAE E. faecalis 
lipoamidase removed protein bound lipoic acid and hydrolyzed methyl lipoate, lipoamide, 
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and lipoyl-lysine as well as other lipoyl amino acids but not biotinyl-lysine, acetyl-lysine or 
benzoyl-lysine. 
The LA-pABA assay is not an unequivocal indicator of lipoamidase activity but it is 
a fast, easy means of screening column fractions. The PDH inactivation/reactivation assay 
is the only assay that eliminates questions about lipoamidase activity. In early experiments 
(Fig. III-3 ) this assay was used to determine lipoamidase in DEAE fractions. I modified 
the assay by recovering inactivated PDH in a spin filtration device, rather than the standard 
pelleting of PDH at 144k x g, so that the assay was much more reproducible. But 
activating system preparations began to further reduce PDH activity instead of recovering 
it. I never resolved this problem; therefore, I lost the ability to establish that PDH 
inactivation was due to lipoamidase removal of lipoic acid instead of something else like 
dissociation of the complex, or protease digestion of the complex. Even in attempts to 
purify the heat and acid stable PS2B protein of the activating system I had trouble with 
activation of apoPDH. Interestingly the activating system positive controls with the PDH 
inactivation/ reactivation assay always activated E.faecalis apoPDH. I have no explanation 
for this. 
The LipDom inactivation assay was used in place of the PDH inactivation ·assay as a 
measurement of lipoic acid removal. This assay can be used after DEAE purification. 
Prior to the DEAE step there is a component that interferes with the analysis. Fig. N-1 
shows that mixing pre-DEAE sample with the LipDom inactivation assay components 
generates almost 8 times more TNB than the amount of lipoyl domain used in the assay. 
After DEAE purification none of this interfering activity remains and the assay is useful but 
I cannot use the LipDom inactivation assay throughout a purification scheme. 
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Figure IV-1. Interference with LipDorn Inactivation Assay. White bars 
represent the average T=O values and black bars represent the average T=3 hr values. 
LipDom indicates lipoyl domain incubated with buffer. AS 1 indicates an ammonium 
sulfate lipoamidase preparation incubated with buffer. AS 1/LD indicates lipoyl domain and 
the ammonium sulfate preparation mixed together. 
I initially planned to examine the yeast activating system 's ability to attach lipoic 
acid to mammalian E2 lipoyl domains. With the receipt of recombinant human lipoyl 
domains from Dr. Roche I was able to make a similar examination with lipoamidase and 
determine that E. faecalis lipoamidase can remove lipoic acid from human lipoyl domain 
resulting in the loss of E3/DTNB activity (Fig. II-5). This is interesting in light of 
Oizumi's findings (38) showing human serum lipoamidase is able to remove lipoic acid 
from bovine PDH only after the PDH had been trypsinized. However, Ravindran et al. 
(64) used partially purified E. faecalis lipoamidase to remove lipoic acid from both the 
complete PDH complex and recombinant domains in a ·study of the role of lipoyl moieties 
in kinase stimulation of mammalian PDH activity. This further indicates that not all 
enzymes called lipoamidase are the same. 
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F. Other Chromatographic Separation Methods Examined 
All chromatography methods discussed in this thesis are based on ionic properties. 
These are the only separation methods that I found to work. Dye affinity chromatography 
was attempted using a test kit consisting of nine different dye conjugated columns from 
Sigma. The mode of binding with dye affinity chromatography is not well defined for any 
given protein and may well involve charge characteristics, affinity binding at the active site, 
regulatory sites or surface affinity. One of the columns showed some promise for 
retaining LA-pABA cleavage activity during initial screening but the results could not be 
repeated. 
Hydrophobic interaction chromatography (HIC) was explored using a Pharmacia 
Hi-Trap HIC test kit consisting of different types of C4 and CS columns. A C4 and a CS 
column were tested. The CS column was selected in an attempt to mimic the S carbon basic 
structure of lipoic acid and attract the lipoamidase active site. Neither the C4 or the CS 
column bound much protein and did not bind any LA-pABA cleaving activity. 
G. Native PAGE 
No combination of chromatographic steps produced homogeneous lipoamidase. 
The HTP column yielded three protein bands in the active peak but I was not able to 
unequivocally associate one with lipoamidase. There is evidence that the EF-Ts 36-37 kDa 
band from the HTP fraction is lipoamidase. However two native PAGE experiments with 
DEAE purified lipoamidase gave a single SDS-PAGE band of -36. One of these native 
PAGE experiments showed a slight reactivation of inactivated PDH (Fig. III-27) and the 
other showed strong LA-pABA hydrolysis. An attempt to sequence this protein was 
unsuccessful. 
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These results show that native PAGE can resolve the DEAE purified proteins to 
single bands. For this reason a great deal of effort was spent trying to establish 
lipoarnidase activity in these fractions. Native PAGE purified protein can be accurately 
assayed for by the LA-pABA cleavage assay but we have already seen that the assay is 
prone to false positive results. The slight reactivation of PDH seen in the slice number 9 
assay was the only increase in PDH activity seen with any of the gel slices. The recovery 
of 5% of a 95% inactivation may not seem very convincing but when all other slices 
showed a further inactivation of PDH, 5% becomes significant. Sequencing of this band 
was unsuccessful. The conditions were not worked out which would allow the LipDom 
inactivation assay to be used successfully with native gel slices. 
H. Lipoamidase Molecular Weight Range Analysis 
Since implementation of the lipoyl domain cleavage assay, all fractions from liquid 
chromatography were initially screened by the LA-pABA assay and then the most active 
fractions were analyzed with the LipDom inactivation assay. Fractions from DEAE (both 
the 0.1 Mand the 0.15 M KCl), MonoQ loaded with both 0.1 M KCl and 0.15 M KCl 
DEAE, and from CHT-II hydroxylapatite showing LA-pABA and lipoyl . domain 
inactivation activity were examined by SDS-PAGE. Figure III-28 shows that none of the 
fractions were homogeneous. It is tempting to compare the band profile versus molecular 
weight profiles of these fractions and say that since only the 31 kDa band is present in all of 
these fractions it must be lipoamidase. This approach does allow me to eliminate proteins 
outside of the 30-40 kDa range. Table III-6 compares the molecular weight and relative 
staining intensity as determined by densitometry of the 30-40 kDa proteins from the 
LipDom inactivation active fractions. From Table III-6 I could say that only the 31 kDa 
protein is present in all fractions but I am not comfortable saying that the protein determined 
to be 36 kDa in HTP is not the same protein determined to be 35 kDa in all of the other 
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fractions. While in theory one should be able to say that a given protein and a given set of 
molecular weight markers will migrate the same way every time, in practice I have found 
this is not necessarily true. I have run two different molecular weight markers (Bio-Rad 
and Sigma) on my gels whenever I have the room and have found them to migrate slightly 
differently relative to each other with every gel. 
Interestingly though a protein of -36 kDa has consistently been prominent in 
various experiments. One of the very first gels run with DEAE active fractions was 
Coomassie Blue stained and showed the major band to be -35-'36 kDa. Also the one native 
PAGE experiment which showed inactivation/reactivation of PDH in a gel slice had a single 
SDS band of -36 kDa. One of the last native slice experiments done showed a strong LA-
pABA cleavage activity in a gel slice and a single SDS band of -36 kDa. Band II from 
HTP, which was sequenced and found to be very similar to UDP-Glucose dehydrogenase, 
migrates at -35 kDa. And the band from a LipDom inactivation active MonoQ fraction 
which was sequenced and identified as EF-Ts migrated at -36 kDa on that gel, although the 
band from HTP which yielded the same sequence migrated at -37-38 kDa. I can 
confidently conclude that lipoamidase is a protein of -35-38 kDa molecular weight. 
I. Further Purification 
Purification calculations (Table III-2) show that lipoamidase was purified 58 fold 
through DEAE chromatography with a 10 % yield. These results were obtained using the 
PDH inactivation assay. Lipoamidase activity in a corresponding sample from a previous 
DEAE column was established by PDH inactivation/reactivation. Application of this 
sample to hydroxylapatite chromatography resulted in 801 fold purification and with less 
than 1 % yield by the PDH inactivation assay. The three protein bands in this fraction were 
sequenced. At this point reactivation of PDH was not possible due to unexplained failure 
of my activating system preparations. Further HTP columns and all MonoQ columns were 
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assayed with the LA-pABA assay and the LipDom inaC?tivation assay was then used to 
establish lipoamidase activity. These two assays do not allow calculation of purification 
starting from crude extract so data was calculated from the DEAE step (Table ill-4). ~ecall 
that a component of the pre-DEAE fraction gives a very high background with the LipDom 
inactivation assay and the LA-pABA assay gives false positives in fractions which do not 
have lipoamidase. None of the fractions with LipDom inactivation activity was purified 
more than 6 fold beyond DEAE but the yield was 60 % or greater. Compare this to the 
_PDH inactivation assay used on HTP fraction II27-29 with -14 fold purification and 5 % 
yield beyond DEAE purification. These levels of purification and recovery are not very 
good but they could be tolerated if the fractions. contained only one or two protein bands. 
None of them do. 
I did not purify lipoamidase to homogeneity. This may be difficult as it has not 
been accomplished in the laboratories of Dr. Lester Reed or Dr. Thomas Roche who are 
very skillful enzymologists. One difficulty is the lack of specificity using model 
·compounds such as LA-pABA as substrate. It is clear there are multiple proteins with 
hydrolytic activity toward LA-pABA. 
Whether the EF-Ts protein that was sequenced from column fractions. which 
. contain lipoamidase activity is really lipoamidase remains an unanswered question. EF-Ts 
has multiple functions including protein elongation, guanylate cyclase activity and initiation 
factor in the RNA phage Q ~ RNA replicase. 
I did purify Elongation Factor Ts from E. faecalis and sequence 86 (amino 
acid 1- 28 and 51-108) amino acids. There is an apparent correlation with PDH 
inactivation in HTP fractions and EF-Ts. EF-Ts is present in MonoQ fractions which have 
LipDominactivation activity. These sequences will be submitted to an appropriate database 
as a putative EF-Ts. 
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J. Summary 
The goal of this project was to purify lipoamidase to homogeneity. An already 
established protocol was used initially and then with hydroxylapatite (HTP) 
chromatography, fractions were obtained which had been purified -800 fold and contained 
three proteins. Sequencing of these three proteins identified two of them as EF-Ts. The 
other was unidentified but contains an NAD+'-binding domain in the amino terminus. 
Various types of chromatography were evaluated for purification but only HTP and anion 
exchange (MonoQ) purified lipoamidase. The three proteins from HTP were not further 
resolved nor significantly enriched. Analysis of band patterns from LipDom inactivation 
active fractions indicate that lipoamidase is a -35-38 kDa protein. EF-Ts sequence was 
obtained from three different protein bands purified from active fractions in two 
chromatographic methods, 86 amino acids of the E. faecalis protein were determined. 
Lipoamidase may correlate with one of the sequenced EF-Ts bands from HTP 
chromatography. . 
103 
Bibliography 
1. Reed, L. J., Gunsalus, I. C., Schnakenberg, G. H. F., Soper, Q. F., Boaz, H. E., Kern, S. F., 
and Parke, T. V. (1953) J. Amer. Chem. Soc. 75, 1267-1270. 
2. Reed, L. J., Leach, F. R., and Koike, M. (1958) J. Biol. Chem. 232, 123-142. 
3. Nawa, H., Brady, W. T., Koike, M., and Reed, L. J. (1960) J. Am. Chem. Soc. 82, 896-903. 
4. Morris, T. W., Reed, K. E., and Cronan, J.E. Jr .. (1994) J. Biol. Chem. 269, 16091-16100. 
5. Hayden, M.A., Huang, I., Bussiere, D. E., and Ashley, G. W. (1992) J. Biol. Chem. 267, 
9512-9515. 
6. Hayden, M.A., Huang, I. Y., Iliopoulos, G., Orozco, M., and Ashley, G. W. (1993) 
Biochemistry 32, 3778-3782. 
7. Reed, K. E. and Cronan, J.E. Jr. . (1993) J. Bacterial. 175, 1325-1336. 
8. Morris, T. W., Reed, K. E., and Cronan, J.E. Jr. . (1995) J. Bacterial. 177, 1-10. 
9. Siggaard-Andersen, M., Wissenbach, M., Chuck, J. A., Svendsen, I., Olsen, J. G., and von 
Wettstein-Knowles, P. (1994) Proc. Natl. Acad. Sci. U.S. A. 91, 11027-11031. 
10. Wada, H., Shintani, D., and Ohlrogge, J. (1997) Proc. Natl. Acad. Sci. U. S. A. 94, 1591-
1596. 
11. Sulo, P. and Martin, N. C. (1993) J. Biol. Chem. 268, 17634-17639. 
12. Brody, S., Oh, C., Hoja, U., and Schweizer, E. (1997) FEES Lett. 408, 217-220. 
13. Jordan, S. W. and Cronan, J.E. (1997) J. Biol. Chem. 272, 17903-17906. 
14. Packer, L., Witt, E. H., and Tritschler, H.J. (1995) Free. Radie. Biol. Med. 19, 227-250. 
15. Bringas, R. and Fernandez, J. (1995) Proteins 21, 303-306. 
16. (1989) Alpha-keto Acid Dehydrogenase Complexes: Organization, Regulation and 
Biomedical Ramifications, Annals of the New York Academy of Science, New York, 
573, N.Y. Roche, T.E., and Patel, M.S., eds. 
17. Reed, L. J. (1974) Acc. Chem. Res. 7, 40-46. 
18. Stepp, L. R., Bleile, D. M., McRorie, D. K., Pettit, F. H., and Reed, L. J. (1981) 
Biochemistry 20, 4555-4560. 
19. Packman, L. C. and Perham, R. N. (1987) Biochem. J. 242, 531-538. 
104 
20. Guest, J. R., Lewis, H. M., Graham, L.D., Packman, L. C., and Perham, R. N. (1985) J. 
Mol. Biol. 185, 743-754. · 
21. Hackert, M. L., Oliver, R. M., and Reed, L. J. (1983) Proc. Natl. Acad. Sci. U.S. A. 80, 
2226-2230. 
22. Yeaman, S. J. (1989) Biochem. J. 257, 625-632. 
23. Quinn, J., Diamond, A.G., Masters, A. K., Brookfield, D. E., Wallis, N. G., and Yeaman, S. 
J. (1993) Biochem. J. 289 ( Pt 1), 8i-85. 
24. Tsunoda, J. N. and Yasunobu, K. T. (1967) Arch. Biochem. Biophys. 118, 395-401. 
25. Fujiwara, K., Okamura-Ikeda, K., and Motokawa, Y. (1997) J. Biol. Chem. 272, 31974-
31978. 
26. Seaman, G. R. and Naschke, M. D. (1955) J. Biol. Chem. 213, 705. 
27. Seaman, G. R. (1953) Proc. Soc. Exptl. Biol. Med. 82, 184. 
28. Seaman, G. R. (1954) J. Amer. Chem. Soc. 76, 1712. 
29. Reed, L. J., Koike, M., Levitch, M. E., and Leach, F. R. (1958) J. Biol. Chem. 232, 143-
158. 
30. Ou, P., Nourooz-Zadeh, J., Tritschler, H.J., and Wolff, S. (1996) Free. Radie. Res. 25, 
337-346. . 
31. Suzuki, K. and Reed, L. J. (1963) J. Biol. Chem. 238, 4021-4025. 
32. Koike, M. and Suzuki, K. (1970) Meth. Enz. 18, 292-298. 
33. Tate, R. J. and Buck, L. (1997) (Unpublished). 
34. Hayakawa, K. and Oizumi, J. (1987) J. Chromatogr. 423, 304-307. 
35. Hayakawa, K. and Oizumi, J. (1988) Enzyme 40, 30-36. 
36. Hayakawa, K. and Oizumi, J. (1988) Biochim. Biophys. Acta 957, 345-351. 
37. Oizumi, J. and Hayakawa, K. (1989) Biochim. Biophys. Acta 991, 410-414. 
38. Oizumi, J. and Hayakawa, K. (1989) Biochem. Biophys. Res. Commun. 162, 658-663. 
39. Oizumi, J. and Hayakawa, K. (1989) Biomed. Chromatogr. 3, 274-275. 
40. Oizumi, J. and Hayakawa, K. (1989) Biofactors 2, 127-129. 
41. Backman-Gullers, B., Hannestad, U., Nilsson, L., and Sorbo, B. (1990) Clin. Chim. Acta 
191, 49-60. 
42. Nilsson, L. and Kagedal, B. (1994) Eur. J. Clin. Chem. Clin. Biochem. 32, 501-509. 
43. Garganta, C. L. and Wolf, B. (1990) Clin. Chim. Acta 189, 313-325. 
44. Nilsson, L. and Ronge, E. (1992) Eur. J. Clin. Chem. Clin. Biochem. 30, 119-126. 
45. Nilsson, L. and Kagedal, B. (1993) Biochem. J. 291, 545-551. 
105 
46. Hui, D. Y., Hayakawa, K., and Oizumi, J. (1993) Biochem. J. 291 ( Pt 1), 65-69. 
47. Oizumi, J. and Hayakawa, K. (1990) Biochem. J. 266, 427-434. 
48. Oizumi, J. and Hayakawa, K. (1990) Biochem. J. 271, 45-49. 
49. Oizumi, J. and Hayakawa, K. (1990) Experientia 46, 459-461. 
50. Oizumi, J. and Hayakawa, K. (1992) Mal. Cell Biochem. 115, 11-17. 
51. Gunsalus, I. C., Dolin, M. I., and Struglia, L. (1952) J. Biol. Chem. 194, 849. 
52. Akins, R. E. and Taun, R. S. (1992) BioTech 12, 496-499. 
53. Bollag, D. M. and Edelstein, S. I. (1991) Protein Methods, Wiley-Liss, New York. 
54. Kalb, V. F. Jr. and Bernlohr, R. W. (1977) Anal. Biochem. 82, 362-371. 
55. (1993) A Practical Guide to Protein and Peptide Purification for Microsequencing, Ch 3. 
Academic Press, Inc., San Diego CA. Matsudaira, P. ed. 
56. Sauve, D. M., Ho, D. T., and Roberge, M. (1995) Anal. Biochem. 226, 362-371. 
57. Whiteman, M., Tritschler, H., and Halliwell, B. (1996) FEBS Lett. 379, 74-76. 
58. Yang, D., Song, J., Wagenknecht, T., and Roche, T. E. (1997) J. Biol. Chem. 272, 6361-
6369. 
59. Korkes, S., del CAmpillo, A., Gunsalus, I. C., and Ochoa, S. (1951) J. Biol. Chem. 193, 
721. 
60. Lipmann, F., and Tuttle, L.C., (1945) J. Biol. Chem. 159, 21-28. 
61. Bratton, A.C., and Marshall, E.K., Jr., (1939) J. Biol. Chem. 128, 537-550. 
62. Christen, U., Quinn, J., Yeaman, S. J., Kenna, J. G., Clarke, J.B., Gandolfi, A. J., and Gut, J. 
(1994) Eur. J. Biochem. 223, 1035-1047. 
63. Liu, S., Baker, J.C., Andrews, P. C., and Roche, T. E. (1995) Arch. Biochem. Biophys. 
316, 926-940. 
64. Ravindran, S., Radke, G. A., Guest, J. R., and Roche, T. E. (1996) J. Biol. Chem. 271, 
653-662. 
65. Altschul, S. F., Gish, W., Miller, W., Myers, E.W., and Lipman, D. J. (1990) J. Mal. Biol. 
215, 403-410. 
66. Worley, K. C., Weise, B. A., and Smith, R. A. (1995) Genet. Res. 5, 173-184. 
67. Dougherty, B. A. and van de Rijn, I. (1993) J. Biol. Chem. 268, 7118-7124. 
68. Wierenga, R. K., Terpstra, P., and Hol, W. G. J. (1986) J. Mo!. Biol. 187, 101-107. 
69. Han, D., Tritschler, H.J., and Packer, L. (1995) Biochem. Biophys. Res. Commun. 207, 
258-264. 
70. Voet, D. and Voet, J. G. (1990) Biochemistry, John Wiley and Sons, New York. 
106 
71. Gendron, N., Breton, R., Champagne, N., and Lapointe, J. (1992) Proc. Natl. Acad. Sci. 
u. s. A. 89, 5389-5392 . 
. 
72. Kostrzewa, M. and Zetsche, K. (1993) Plant Mol. Biol. 23, 67-76. 
73. Xin, H., Woriax, V., Burkhart, W., and Spremulli, L. (1995) J. Biol. Chem. 270, 17243-
17~49. 
74. Macchia, V., Consiglio, E., and Varrone, S. (1977) C. R. Seances. Soc. Biol. 171, 516-
525. . 
75. Kondo, M. (1975) Arch. Int. Physiol. Biochim. 83, 909-948. 
76. Blumenthal, T., Young, R.A., and Brown, S. (1976) J. Biol. Chem. 251, 2740-2743. 
77. Ross, RP., and Claiborne, A. (1992) J. Mol. Biol. 227, 658-671. 
78. Kolberg, J., Hoiby, E.A., Lopez, R., and Sletten, K. (1997) Microbiology 143, 55-61. 
107 
Vitae 
Ronald Jay Tate 
Candidate for the Degree of 
Doctor of Philosophy 
Thesis: Lipoamidase From Enterococcus faecalis 
Major Field: Biochemistry 
Biographical: 
Personal Data: Born in Durango Colorado on April 19, 1963 to John and Vivian 
Tate; married to Christina Kay Frizell on May 19, 1984; we have four 
children, Hunter (4), Nathaniel (2), Katherine (1), and Victoria (infant). 
Education: Graduated from Bayfield High School, Bayfield Colorado in May 1981; 
received Bachelor of Science degree (Summa Cum Laude) in Cellular and 
Molecular Biology from Fon: Lewis College, Durango Colorado in May 1991; 
Completed the requirements for the Doctor of Philosophy degree with a major 
in Biochemistry at Oklahoma State University in July 1998. 
Experience: Enlisted in tile. United States Army in 1982 and served four years; 
. employed as an electrician during the summers while getting my bachelors 
degree from 1987 to 1991; employed as a graduate research assistant in the 
Department of Biochemistry at Oklahoma State University from 1991 to 1997; 
employed as a research associate at the H.L. Snyder Memorial Research 
Foundation fro~ 1997 to present. 
Professional Memberships: Phi Lambda Upsilon. 
